#version: 0.2
i n
t i
r e
t h
a n
e n
e r
e d</w>
o n
o f</w>
a t
r o
i n</w>
th e</w>
i t
a ti
a r
an d</w>
o n</w>
s i
a l
s t
a l</w>
o r
i c
a s
d i
e c
en t
a c
l o
in g</w>
d e
o r</w>
a s</w>
u r
t o</w>
e r</w>
w it
u l
wit h</w>
s e
o m
a m
o l
u c
e s
re s
o c
l y</w>
in e</w>
l e
en t</w>
p h
p ro
o u
p ati
c on
r i
w as</w>
d uc
ati on</w>
T h
er e</w>
v e</w>
i d
e s</w>
at ed</w>
a d
o s
v e
s .</w>
h e
p er
f f
a t</w>
i s</w>
a n</w>
i c</w>
m e
o t
a g
a p
i l
w ere</w>
ent s</w>
u s
c h
c e
i m
duc ed</w>
ti on</w>
i s
a b
t re
h y
t er
c om
t r
f or</w>
Th e</w>
p a
s u
n e
in e
o x
ec t
b y</w>
u n
pati ents</w>
e x
in duced</w>
b e
p l
re n
v er
e ff
ati on
in c
w e
e n</w>
r at
h i
a r</w>
it y</w>
m ent</w>
t er</w>
s ,</w>
p res
re as
a f
re d</w>
c ar
i f
m in
th at</w>
u t
h a
n o
c e</w>
s y
ti on
o p
g n
l i
t e
0 .
u d
l e</w>
r a
- induced</w>
m a
an t
ti c</w>
af ter</w>
tre at
m o
y .</w>
p re
v i
w h
g /
i st
at e</w>
ro u
p t
e m
th er
p or
con t
ti ve</w>
i z
u m
si on</w>
q u
ic al</w>
c l
) .</w>
e p
si gn
as e</w>
an t</w>
d o
ul ar</w>
c o
r u
m on
p o
th e
d a
b e</w>
e t
h o
u m</w>
on e</w>
g h
ur e</w>
ou s</w>
p ar
in f
d .</w>
os e</w>
re ce
i r
inc reas
no t</w>
if ic
car di
ther ap
s er
m g/
ect s</w>
an ti
treat ment</w>
g rou
res p
si s</w>
an g
sign ific
th er</w>
) ,</w>
or m
y ,</w>
e l
v ed</w>
g en
ent r
in g
i a</w>
b u
s e</w>
ar y</w>
lo w
m ic
d ru
u re
min ist
y l
hy per
ti v
c or
m or
as s
ad minist
e v
oc i
c a
ro m</w>
en ce</w>
I n</w>
t en
lo g
si on
d ur
f rom</w>
s p
o b
al ly</w>
e .</w>
re l
ti c
u ro
ass oci
lo p
u s</w>
S :</w>
pa th
eff ec
di s
th is</w>
t a
st ud
e ar
in d
eff ects</w>
re por
ar e</w>
es e</w>
tr a
b lo
us e</w>
de ve
p ot
tre ated</w>
ha d</w>
i d</w>
oc a
t ed</w>
ox ic
d ose</w>
O N
ve l
a z
t s</w>
d er
s ho
i o
deve lop
e st
ro m
th an</w>
associ ated</w>
e ,</w>
mg/ k
i th
se s</w>
su b
ti m
c ur
ac tiv
dur ing</w>
+ /
0. 0
f ol
f i
ou n
ation s</w>
cont ro
bu t</w>
m y
s c
o l</w>
resp on
ut e</w>
in j
id e</w>
ne uro
or y</w>
c y
o log
un c
l l
pot en
w ith
r an
administ r
rece i
ma y</w>
d ec
us ed</w>
v en
res ul
effec t</w>
pati ent
am ine</w>
i ti
rat s</w>
l l</w>
m ent
ren al</w>
stud y</w>
g h</w>
pati ent</w>
( 1
in ed</w>
p os
W e</w>
b o
o d</w>
ff e
en d
an c
in ter
i a
ati ve</w>
d ,</w>
be en</w>
tr an
v er</w>
+/ -</w>
therap y</w>
da y
t oxic
d y
ar di
grou p
n orm
si ve</w>
ag e</w>
es s</w>
ac t
signific ant
hi b
pres s
r on
c oca
d e</w>
fol low
es t</w>
we e
ha ve</w>
f unc
es .</w>
increas ed</w>
w he
com p
al l</w>
ation .</w>
be t
a il
al u
p i
f l
dec reas
sy n
significant ly</w>
0 0</w>
ot h</w>
ch ang
se iz
- 1
c entr
g g
u b
wh o</w>
cl in
me th
t w
l on
y ear
g i
mic ro
dru g
le vel
ac ute</w>
ic h</w>
en c
an ce</w>
administr ation</w>
n o</w>
wh ich</w>
v as
in tra
in v
at e
rece pt
ec h
su gg
am in
u di
( 2
ri s
in hib
or s</w>
grou p</w>
ag on
he m
ou t</w>
he ar
s t</w>
ffe ren
h as</w>
t ri
ab le</w>
re e</w>
f ail
id ence</w>
sho w
hi gh
di se
g l
signific ant</w>
gh t</w>
ob ser
s o</w>
p e
st udi
ve n</w>
cardi a
th ese</w>
S I
g r
d ro
g ra
dru g</w>
we en</w>
ec tion</w>
blo od</w>
develop ed</w>
bet ween</w>
re qu
ou r</w>
m pt
c ase</w>
oc ardi
an al
ul d</w>
v entr
di fferen
b oth</w>
ec tive</w>
pro te
Th is</w>
activ ity</w>
st r
me di
tran s
pa red</w>
al so</w>
s en
ine -induced</w>
sy st
wee k
de p
ventr ic
ine .</w>
f orm
f or
al l
si b
oc cur
1 .
b r
tion s</w>
i al</w>
re at
tw o</w>
ect ed</w>
rel ated</w>
o ther</w>
ure s</w>
c as
ine ,</w>
it s</w>
rat e</w>
clin ical</w>
i t</w>
m a</w>
ph en
de r</w>
d ic
com pared</w>
s ec
re c
tion .</w>
in u
ti al</w>
iz ed</w>
m an
lon g
m il
5 -
C L
mpt om
e th
es ,</w>
level s</w>
er g
tr ac
f ir
al s</w>
pl ic
n on
cardia c</w>
M E
mor e</w>
ventric ular</w>
cont inu
a st
i de
m g</w>
g e
mg/k g
t o
ol d</w>
v ing</w>
coca ine</w>
ver ,</w>
al o
p ri
SI ON
% )</w>
a in
u sion</w>
te st
lo w</w>
c lo
duc tion</w>
con centr
y p
hyper ten
R E
hear t</w>
ar i
ar ter
per i
S U
pl as
0 0
he pati
mo de
ev alu
c al
er al</w>
ec ti
d om
s ur
c ular</w>
increas e</w>
do ses</w>
si a</w>
resul ts</w>
contro l</w>
ris k</w>
C ON
se s
dep end
ep i
ou s
di d</w>
CL U
CON CLU
ti s</w>
CONCLU SION
sy mptom
m i
e -
si st
ne ph
Th ese</w>
b l
ver se</w>
se v
mon th
th i
A C
n it
re g
ch ol
an im
day s</w>
rat s.</w>
i .
y c
he mo
inc l
ch ron
com b
es the
show ed</w>
m al
recei ved</w>
treat ment
le p
ech an
blo c
do se
L T
a x
inhib it
ti g
toxic ity</w>
l ess</w>
si de</w>
my ocardi
m at
le v
u e</w>
l at
dy s
c i
il e</w>
norm al</w>
I n
su p
da y</w>
m echan
o ph
ation ,</w>
T H
it y.</w>
hy poten
follow ing</w>
path y</w>
press ure</w>
s ti
th rom
5 0</w>
ant agon
obser ved</w>
sev ere</w>
e i
2 .
func tion</w>
respon se</w>
is o
u se
T I
hi st
ac tion</w>
li ver</w>
mg/k g</w>
ven ous</w>
b as
an e
oun d</w>
ul ation</w>
o di
de ter
ar k
hy th
e d.</w>
v al
pa in</w>
incl ud
r hyth
oc y
v ul
we ver,</w>
SU LT
e d
at ing</w>
RE SULT
me as
or al</w>
de f
pl ac
an d
in al</w>
repor ted</w>
t ac
RESULT S:</w>
gra ph
ol y
po st
O D
chang es</w>
1 0</w>
il ity</w>
repor t</w>
tion ,</w>
s uc
chron ic</w>
f e
sib le</w>
recept or</w>
ri b
whe n</w>
se l
il l
us ing</w>
os t</w>
on ly</w>
d op
ind ic
k e</w>
ser um</w>
f act
m us
es tig
ic in</w>
ine -
e red</w>
t ro
comp le
' s</w>
l im
er s</w>
me an</w>
inv estig
m un
per id
myocardi al</w>
in .</w>
ME TH
pres sion</w>
l it
y m
olog ical</w>
ati c</w>
vas cular</w>
pres ent</w>
erg ic</w>
fail ure</w>
neph ro
in ,</w>
ar c
as ses
w e</w>
ous ly</w>
ad verse</w>
con vul
h or
hy dro
b ra
os ph
1 0
s ed</w>
5 %</w>
with out</w>
ce ll
t h</w>
th ree</w>
un der
bloc k
METH OD
decreas ed</w>
therap y.</w>
fi b
per io
- old</w>
y -
pro t
st er
c an</w>
th ou
in -
mechan is
p it
me t
fir st</w>
anal y
inc idence</w>
for e</w>
at ri
2 -
f requ
epi lep
E C
g lo
resp ecti
ex pos
ia .</w>
ph osph
v ari
gi ven</w>
cas es</w>
re duced</w>
w om
ab ol
tim e</w>
( P
i l</w>
a .</w>
inj ection</w>
b i
ver y</w>
d at
sugg est</w>
ad e</w>
u al</w>
sion .</w>
ar rhyth
recei ving</w>
d rom
i r</w>
m ost</w>
tion al</w>
si s.</w>
d ue</w>
u p
c at
3 .
patient s.</w>
administ ered</w>
s tim
al ph
de sc
si mil
hi gh</w>
ect ro
inf l
sen si
n er
t ing</w>
plas ma</w>
com plic
dise ase</w>
p at
in iti
ar g
im mun
comb in
as t</w>
re f
seiz ures</w>
plac e
en z
syn drom
f ound</w>
s y</w>
b le
im pro
ha vi
p r
em ia</w>
T o</w>
fl u
th ose</w>
pre vi
sion s</w>
respecti vel
hy po
ocy t
ac et
sec on
ia ,</w>
( A
an esthe
s )</w>
sho uld</w>
m it
t ot
H o
sp ec
f ind
o re
METHOD S:</w>
m ac
2 0</w>
sugg est
ent ed</w>
thou gh</w>
c ap
m er
s al
ma in
sy ch
( C
ca used</w>
sub j
h alo
year -old</w>
x im
il d
high er</w>
cardi o
we ll</w>
contro l
syst em
d ox
be havi
eff ect
com m
inf usion</w>
enc y</w>
ing s</w>
P A
intra venous</w>
duc e</w>
se qu
depend ent</w>
a ff
ei ther</w>
ent ly</w>
ad ren
per im
ce ll</w>
dise as
occur red</w>
t yp
c anc
sion ,</w>
gen er
mic e</w>
week s</w>
on ary</w>
a y
syndrom e</w>
symptom s</w>
studi es</w>
o gen
it e</w>
m ark
or ub
3 0</w>
ac id</w>
d am
simil ar</w>
the ir</w>
am p
p sych
gr am
de mon
be fore</w>
ve l</w>
re co
ou t
el ectro
ad di
d s</w>
( P</w>
h e</w>
d ra
re ac
group s</w>
pro g
si de
p er</w>
Ho wever,</w>
ran dom
norm al
no w
ce re
develop ment</w>
CONCLUSION S:</w>
bra in</w>
di ag
s om
com par
k g
C A
f t</w>
ve ly</w>
po si
en ti
e m</w>
r h
es s
in -induced</w>
at al</w>
ec t</w>
k now
A l
ne ur
lo s
drug s</w>
ic i
a ,</w>
vi e
V E
a v
k e
m ul
1 9
3 -
pro duced</w>
o ver</w>
k ine
dra w
4 -
cor onary</w>
dis continu
re ver
t ol
k ing</w>
dat a</w>
met abol
d ed</w>
en ce
m s</w>
5 0
ol e</w>
cur ren
ter m</w>
p ine</w>
ex perim
U N
m ia</w>
c hem
treatment .</w>
per form
mor ph
c ul
decreas e</w>
st at
combin ation</w>
ph y
inv ol
tot al</w>
c hemo
ure .</w>
o ver
month s</w>
in to</w>
am ide</w>
ch ild
R O
ox y
n ec
be ta
dis or
with in</w>
it y,</w>
t ox
se ver
m in</w>
ar ac
r ang
c le
low er</w>
ab ility</w>
e d,</w>
b ut
re t
um b
ti s
ro le</w>
dox orub
pre v
b ec
anim als</w>
with draw
ac h</w>
tol er
s ul
hypoten sion</w>
di st
L -
we i
suc h</w>
is t</w>
y o
4 .
i ly</w>
wh ile</w>
cardi a</w>
0.0 0
trans pl
non -
am ph
g reat
por t
r ine</w>
v alu
v al</w>
id ine</w>
ot or</w>
r at</w>
e lev
on e
( 3
u red</w>
mode l</w>
ca use</w>
1 2</w>
lo c
I t</w>
ol ic</w>
l or
ic ac
m is
ox id
mg/ m
e u
me dic
Th ere</w>
% ,</w>
br al</w>
u res
pi lo
s on
ic ally</w>
ho ur
find ings</w>
re gi
ra di
ane ous</w>
effec tive</w>
ex c
I I
v id
ar mac
f our</w>
c le</w>
th ere</w>
) -
A f
et y</w>
i p
le ft</w>
tac hy
z ed</w>
throm bo
h um
i es</w>
o per
M A
u r</w>
az ep
op en
sur g
at es</w>
uc le
t ub
dose -
o id
al e</w>
cy clo
1 -
e re
v ol
do g
t um
olog ic</w>
re as</w>
de s</w>
cat al
se t</w>
con cl
an y</w>
t e</w>
re ve
dy n
al ed</w>
ot oxic
i red</w>
5 .
eff icac
patient s,</w>
ur al</w>
d ing</w>
ent al</w>
pro long
- term</w>
a y</w>
u p</w>
d os
inf arc
re vie
m ents</w>
( S
K G
ant s</w>
halo perid
( 0.
le vel</w>
alph a
T w
concentr ations</w>
anc ed</w>
hepati c</w>
m ic</w>
1 5</w>
s af
ex peri
mode l
arter ial</w>
differen t</w>
is h
- dose</w>
v it
con di
B AC
s ing
a use</w>
RO UN
KG ROUN
BAC KGROUN
2 4</w>
da ily</w>
ap pro
meth yl
co uld</w>
c in
m ol
k in
A n
m ine</w>
prog res
pilo car
inj ur
at ory</w>
li thi
de t
arac ter
e tic</w>
y l</w>
poten tial</w>
s odi
ag ain
great er</w>
pe a
inj ec
micro gram
ing .</w>
p ac
an e</w>
O B
si s,</w>
re duction</w>
J EC
A N
ph eral</w>
d ul
Af ter</w>
im pa
ex am
pro p
bas el
again st</w>
c ol
u l</w>
in ary</w>
g en</w>
ar b
en s
0.0 5
hyperten sion</w>
ch aracter
stim ul
s a
ing ,</w>
l ab
. )</w>
l ine</w>
includ ing</w>
car b
f em
7 .
TI VE
bo d
OB JEC
o id</w>
al ter
l in
di ab
oca ine</w>
amph et
studi ed</w>
g o
OBJEC TIVE
at ten
is chem
glo mer
ad y
neur on
co ur
w ar
1 )</w>
p ul
6 -
hepati tis</w>
lo l</w>
dop amine</w>
ph armac
ur ther</w>
phy si
i ous</w>
2 0
mg/kg )</w>
6 .
( p</w>
ev idence</w>
on g</w>
i tion</w>
on ic</w>
am e</w>
o graph
p p
nit ro
reve aled</w>
pos sible</w>
n umb
BACKGROUN D
str uc
ro p
r ac
on set</w>
e ach</w>
ve ment</w>
year s</w>
prote in</w>
al ,</w>
meas ured</w>
ate ly</w>
am e
os pit
cell s</w>
beta -
prote in
pri m
en h
peri pheral</w>
centr al</w>
infl am
bod y</w>
l id
us ,</w>
N T
mon it
O n
br ady
1 ).</w>
follow ed</w>
dur ation</w>
yc in</w>
th al
iti es</w>
comm on</w>
S E
BACKGROUND :</w>
mal e</w>
th rou
l if
im port
ent an
A d
ac ti
p y
vi r
ch lor
catal ep
it ed</w>
v ac
tic s</w>
P ati
n a
o f
ll ed</w>
on t
perform ed</w>
G rou
ap p
seiz ure</w>
eu tic</w>
n ic
ad en
4 0</w>
antagon ist
A ll</w>
id enti
sodi um</w>
ri c</w>
( n</w>
poten ti
tic al</w>
s m
previ ously</w>
posi tive</w>
ad ul
c um
CONCLUSION :</w>
f low</w>
a in</w>
re ,</w>
po in
whe ther</w>
A D
Al though</w>
f ul
efficac y</w>
ge si
de x
evalu ated</w>
o d
ine ph
concentr ation</w>
chol est
wee k</w>
fl ur
t ly</w>
is m</w>
ta ined</w>
therap eutic</w>
1 ,</w>
N A</w>
y e
ma j
s ol
di vid
mg/kg ,</w>
mus cle</w>
he mor
b il
cere bral</w>
a d</w>
6 0</w>
he pat
re n</w>
l y
p oly
canc er</w>
curren t</w>
str ated</w>
c es</w>
pro po
ur ia</w>
hemor rh
enz ym
desc ri
A B
mic e.</w>
c is
stat us</w>
le u
secon d
n i
know n</w>
cardi om
cal ci
- treated</w>
ar ly</w>
an s</w>
pl e</w>
par tic
ce p
om a</w>
2 5</w>
perio d</w>
expos ure</w>
t .</w>
re duc
re cor
( N
ex pression</w>
an a
tiv ity</w>
st res
throm b
t est</w>
ear ly</w>
i. p
f en
ati n</w>
an ce
som e</w>
h ospit
ish ed</w>
child ren</w>
2 ,</w>
tox ic</w>
path y.</w>
s /
deter mine</w>
9 5%</w>
dyn am
typ e</w>
sing le</w>
r am
syst em</w>
id ne
Pati ents</w>
al .</w>
te m
k ed</w>
c oun
f ac
d ou
anti -
r ati
8 .
s hor
deter min
( D
basel ine</w>
s us
o st
S )</w>
( H
respon ses</w>
a ined</w>
demon strated</w>
az ol
hyper al
N o</w>
er .</w>
diag no
withdraw al</w>
enc ed</w>
los s</w>
con sist
N e
leu k
ac id
f urther</w>
1 00</w>
c ent
in ine</w>
numb er</w>
long -term</w>
whe reas</w>
al y
C h
z ap
oc amp
analy sis</w>
pri or</w>
ab normal
hi pp
en e
u tion</w>
mon ary</w>
l y,</w>
lit er
recept ors</w>
k idne
fi ed</w>
subj ects</w>
b o</w>
disor der
cardio vascular</w>
gl ut
m g
psych o
c ess
asses sed</w>
( 4
a th
si x</w>
i. v
c it
c er
P )</w>
seiz ures
I I</w>
re sist
P ro
pro duc
place bo</w>
hipp ocamp
de l
as si
di rec
chang e</w>
ation s.</w>
transpl ant
fi ve</w>
diseas e.</w>
bec ause</w>
convul s
al ity</w>
A c
system ic</w>
el l
includ ed</w>
A )</w>
ur inary</w>
nic ot
fact ors</w>
ep iso
ence ph
ac tive</w>
st ar
OBJECTIVE :</w>
r ap
oc h
c reat
in trac
i v
s hi
s :</w>
on e.</w>
in ten
( M
re le
mul ti
respectivel y.</w>
medi an</w>
pro b
A T
ad v
or ph
gl yc
exam ined</w>
0 %</w>
differen ces</w>
se en</w>
S T
surg er
sel ective</w>
rib ed</w>
olog y</w>
t ,</w>
stud y.</w>
ro s
he par
sur vi
e de
st ro
am ong</w>
R e
pro st
hour s</w>
hist ory</w>
hum an</w>
st ri
increas es</w>
mechanis m</w>
investig ated</w>
ti es</w>
prote ren
indic ate</w>
A M
tis su
in duc
f er
app ear
sub st
doxorub icin</w>
p ir
inf u
C om
u lo
ang io
ud e</w>
o -
min ut
bl ad
arter y</w>
w or
5 ,</w>
me n</w>
f entan
0 -
ge sia</w>
Grou p</w>
li ke</w>
- 1</w>
sensi tivity</w>
a u
sp inal</w>
cardiom yo
he ad
is ol
a w
oper ative</w>
prolong ed</w>
m m
he al
2 )</w>
resul ted</w>
sp ont
lithi um</w>
hyperten sive</w>
r it
ol -induced</w>
c ir
m en
experim ental</w>
su s</w>
ne w</w>
f ul</w>
atten u
ag e
A I
ren ce</w>
pres ented</w>
if ic</w>
- bl
otoxic ity</w>
chemo therapy</w>
l as
iz ation</w>
e l</w>
dys kine
ma xim
wom en</w>
liter at
medi ated</w>
gl uc
hydro x
f ol</w>
p le
ner v
f ic
8 -
second ary</w>
am ide
pres ent
re s</w>
pro f
contro lled</w>
e ti
E ff
% ),</w>
wei ght</w>
j u
mechanis ms</w>
sc op
ag ent</w>
maj or</w>
de press
ab s
ver sus</w>
cl on
G AB
iti s</w>
ev ents</w>
ag ent
the li
throu gh</w>
import ant</w>
calci um</w>
rat es</w>
spec ific</w>
n ucle
a ut
I C
dou ble
re st
bi op
in duction</w>
ro sis</w>
ate d.</w>
A t</w>
% ).</w>
dro me
cap sa
arrhyth mi
i ed</w>
dis c
ti co
pres su
le s</w>
am eth
frequ ency</w>
car cin
atri c</w>
ra z
syn drome
inhib ition</w>
m otor</w>
lo ro
associ ation</w>
en do
Tw o</w>
iso proteren
group s.</w>
v is
prim ary</w>
en g
dys function</w>
toxic ity.</w>
P re
ox ide</w>
N -
head ac
neuro pathy</w>
D E
s ame</w>
ster oid
p op
hem at
a k
1 4
inflam mat
cy t
pa m</w>
fem ale</w>
di ff
n ot
( E
tachy cardia</w>
ic e</w>
un der</w>
wom an</w>
ar d</w>
elev ated</w>
H B
a si
vac a
n ess</w>
er ,</w>
ati s
ab l
st and
o ro
infl u
m .</w>
alpha -
cyclo phosph
ab ly</w>
arb it
1 4</w>
ti s.</w>
pl us</w>
inflammat ory</w>
lid ocaine</w>
k al
tran si
pi vaca
comple te</w>
fib ri
con trac
con side
t al</w>
con f
res ol
experi enced</w>
ph ase</w>
or s.</w>
g u
P O
sup por
pul monary</w>
pre treatment</w>
differen ce</w>
ain ing</w>
l arg
m l
convuls ant</w>
ti l
impa ir
glo b
b ol
al one</w>
lit ax
i gn
o m</w>
k et
ag ents</w>
on i
neuro log
ta king</w>
s ;</w>
o lol</w>
1 3
u ally</w>
propo fol</w>
fibri ll
e qu
double -bl
ur ine</w>
tri al</w>
re ma
m m</w>
n ing</w>
rat s,</w>
d oc
antagon ist</w>
C on
on e,</w>
oc c
dam age</w>
9 .
repor ts</w>
o sis</w>
gr ade</w>
injur y</w>
random ized</w>
M D
place bo
in duce</w>
( -1
m b
( T
inj ected</w>
ho wever,</w>
u ses</w>
sub sequ
pres ence</w>
e pam</w>
agon ist
stim ulation</w>
S t
blad der</w>
at eral</w>
5- H
f o
u s.</w>
out com
1 2
v s</w>
c ut
x i
ac in</w>
O ur</w>
e ven</w>
diagno sis</w>
show n</w>
stud y,</w>
m ag
de g
administr ation.</w>
+/ -
res h
dynam ic</w>
dog s</w>
an emia</w>
sever al</w>
7 -
se d
ation shi
p ent
gen ic</w>
cour se</w>
amphet amine</w>
re tion</w>
hy p
C I
treatment ,</w>
ex amin
in d</w>
fail ure.</w>
n os
struc t
ot on
t y</w>
stres s</w>
ogen e
enceph alo
con tr
b ac
s in
re pe
p en
b enz
sal ine</w>
s ).</w>
D -
s o
py ri
pre dic
per f
tic ally</w>
secon d</w>
m id
infarc tion</w>
group .</w>
a re
A n</w>
follow -
1 1</w>
ye ar</w>
reac tions</w>
therap y,</w>
initi al</w>
On e</w>
pro l
ag e,</w>
rel ationshi
previ ous</w>
- related</w>
ana esthe
saf ety</w>
op io
su ff
sp ective</w>
fact or</w>
as pir
i g
effect s.</w>
ne g
s it
comb ined</w>
ab out</w>
t op
mo der
str ic
li ke
( 5
t y-
th resh
ro w
os ine</w>
ocyt open
discontinu ation</w>
is on</w>
ay ed</w>
le ast</w>
d ar
in divid
d -
conside red</w>
a ver
per sist
te d.</w>
m an</w>
li p
in tr
glomer ular</w>
cum ul
pos sib
oc ic
ob arbit
inter val</w>
ur ing</w>
func tion.</w>
pre gn
pac litax
mark ed</w>
behavi oral</w>
bas ed</w>
rang e</w>
l ym
c an
1 6</w>
par t
on d
the sis</w>
t en</w>
resul t</w>
al ine</w>
ure ,</w>
ro lim
ineph rine</w>
determin ed</w>
ag e.</w>
expos ed</w>
regi on
oc hem
mil d</w>
my o
c ent</w>
inhibit or</w>
f ree</w>
(2 )</w>
at h</w>
er y
adul t</w>
prot ective</w>
pilocar p
ell ular</w>
al s.</w>
sever ity</w>
p tion</w>
i di
g ast
evalu ate</w>
s co
high -dose</w>
cor rel
con fir
atri al</w>
in o
I V</w>
ner ve</w>
descri be</w>
demon st
v s.</w>
diab etic</w>
) ;</w>
pat ter
ap pea
ang i
activ ation</w>
P A</w>
the y</w>
impro ved</w>
epilep tic
cont rib
diag nos
b le</w>
mor t
AN D</w>
tim es</w>
rati o</w>
phen y
oph yl
haloperid ol</w>
az epam</w>
catalep sy</w>
a sis</w>
the tic</w>
pa ren
e very</w>
anal gesi
suggest s</w>
I S
en d</w>
b io
thromb ocytopen
ch loro
ex er
( L
( -
zap ine</w>
ri pt
or g
inter sti
heal th
b ro
am in</w>
d r
1 7
requ ired</w>
st e
sen s
C a
1 3</w>
revie w</w>
ol ,</w>
re tro
y n
ob tained</w>
con tra
1 5
re action</w>
im en
s h
re x
rat ory</w>
acet yl
disc us
ti zed</w>
me mb
ser oton
sul f
lym ph
ame ter
ic ill
de li
3 ,</w>
reas t</w>
i f</w>
f oc
complic ations</w>
um .</w>
2 00
t u
qu in
microgram s/
inc e</w>
0 ,</w>
ph yl
valu es</w>
lev o
1 8</w>
intersti tial</w>
M e
and /
D i
tre m
my e
m es
and/ or</w>
2 %</w>
y ro
ta k
de ath</w>
H y
obser v
invol ved</w>
ev ent
enzym e</w>
le sions</w>
io dar
rele ase</w>
ol .</w>
ment al</w>
all y,</w>
ate le
th en</w>
b reast</w>
suggest ed</w>
reco very</w>
n al</w>
fe at
1 %</w>
ri am
aly sis</w>
vi v
respon se
I V
monit or
com mon
y oun
tion s.</w>
it ing</w>
a m</w>
al ized</w>
se d.</w>
day s.</w>
al though</w>
t -
s k
e pt
E x
pl atin</w>
glyc er
b ind
ag es</w>
1 8
val pro
like ly</w>
oly tic</w>
hor mon
sign s</w>
l y.</w>
azep ine</w>
y st
l u
P ark
O n</w>
( 6
sy m
ma z
mo di
bu pivaca
nerv ous</w>
mis sion</w>
epilep tic</w>
complic ation</w>
activ ity.</w>
phen yl
mi ght</w>
i or</w>
per it
Ac ute</w>
ve ,</w>
rema ined</w>
ati vely</w>
alph a</w>
st ,</w>
ocic ep
rever sible</w>
go ing</w>
Park in
D O
n or
enh anced</w>
be ing</w>
use .</w>
sm all</w>
ro ph
( B
ri tis</w>
lo x
ic in-induced</w>
P h
A L
k g</w>
C O
wei gh
adv anced</w>
m ou
P -
1 6
tum or</w>
loc al</w>
H g
man if
en ing</w>
P T
C lin
D )</w>
tissu e</w>
p ur
e t</w>
brady cardia</w>
p ec
le .</w>
ex pl
ery th
3 %</w>
B oth</w>
ot ens
an ne
abnormal ities</w>
ve d.</w>
relationshi p</w>
ref le
pro per
pl atele
b ene
kidne y</w>
col l
as s</w>
prop ran
def ici
syst olic</w>
morph ine</w>
R )</w>
pro ce
. ,</w>
ven tion</w>
pilocar pine</w>
con duc
adren ergic</w>
seizures .</w>
hyperal gesia</w>
health y</w>
c op
W he
ser ious</w>
ac hi
ad ju
ex trac
vol um
te red</w>
i ratory</w>
or atory</w>
N S
v es</w>
mye lo
appea red</w>
st atis
par ameter
g row
do es</w>
me mor
creat inine</w>
addi tion,</w>
f -
di g
character is
tro ph
perit one
na use
desc ribed</w>
co ag
ation al</w>
r he
Th e
test ed</w>
ri l</w>
group ,</w>
re .</w>
min im
eth yl
a thi
tem por
re main
memb ran
me d
ca uses</w>
ox if
g ran
cumul ative</w>
ation s,</w>
( 7
A -
pot assi
resp iratory</w>
glut am
transi ent</w>
multi ple</w>
me ta
drug .</w>
ch anne
asses s
si a.</w>
vit amin</w>
o path
O f</w>
tub ular</w>
ri st
reco gn
minut es</w>
st ained</w>
investig ate</w>
week s.</w>
r ing</w>
graph ic</w>
con ver
coca ine-
m uc
de pres
ab dom
theli al</w>
occur rence</w>
hydrox y
um ,</w>
ev o
direc t</w>
19 9
( 8
cut aneous</w>
aff ected</w>
m ed</w>
cont aining</w>
re d.</w>
vari ous</w>
spont aneous</w>
ot yp
ex hib
n al
f r
ay s</w>
ab il
for m</w>
contr ast</w>
S E</w>
or s
par tial</w>
occ ur</w>
injec tions</w>
convul sions</w>
c y</w>
mg/m 2</w>
prev ented</w>
continu ous</w>
anesthe sia</w>
vas cul
rel ative</w>
med ical</w>
ap am
ag ed</w>
re p
manif est
bloc k</w>
0.05 ).</w>
ex ten
impro vement</w>
ri al</w>
pro v
pro duce</w>
de ath
chol in
ar th
a i
D uring</w>
( R
sho w</w>
in s</w>
identi fied</w>
H g</w>
r are</w>
l ,</w>
immun o
angi otens
C B
i.v .</w>
ei ght</w>
Parkin son
prev ent</w>
pres c
poin t
t ent</w>
anim al</w>
am iodar
se ven</w>
M T
( O
s ch
de pression</w>
a c</w>
s mo
re comm
(1 .
xim ately</w>
i tive</w>
ede ma</w>
asses s</w>
a ro
th ir
i ally</w>
( G
frequ ently</w>
dos age</w>
5-H T
ri ght</w>
l ac
survi val</w>
sign ed</w>
moder ate</w>
neuron s</w>
inhibit ed</w>
R NA</w>
4 %</w>
( +
Th ree</w>
ograph y</w>
form ation</w>
reg imen
ochem ical</w>
res t</w>
or ,</w>
meas ure
doc um
gl y
agon ist</w>
compar ison</w>
% .</w>
pot ent</w>
es tive</w>
E R
1 ),</w>
pharmac o
ameth as
ogen ic</w>
mal ign
comple te
appear s</w>
an xi
we ll
cor e</w>
ti me
suff ici
ischem ic</w>
est abl
ud ed</w>
d n
ca ffe
anc es</w>
H C
mit ted</w>
er o
abs ence</w>
2 1</w>
p an
im medi
co gn
ud ine</w>
s .
respectivel y
monitor ing</w>
com it
an d,</w>
lo com
ch est</w>
N a
pro c
im plic
w at
l ast
cle ar
proce d
flur ane</w>
increas ing</w>
halo th
h er</w>
s -
ri g
em ic</w>
ech ocardi
bind ing</w>
ane ously</w>
addi tion</w>
suggest ing</w>
neuro lep
influ ence</w>
diab et
cy sti
em ia.</w>
drug s.</w>
amin o
se x
in test
control s</w>
ot rop
medic ation</w>
k s</w>
w ide
under going</w>
syndrome .</w>
contra st,</w>
sy .</w>
l am
il tr
es s,</w>
nicot ine</w>
episo des</w>
6 %</w>
w ent</w>
s ity</w>
post -
le ad
dop a</w>
och ond
m al</w>
1 ,
of ten</w>
follow- up</w>
biop sy</w>
ti z
cep ti
th ec
protein uria</w>
di l
micro g/
m ar
amin ergic</w>
sin us</w>
hyper troph
adren oc
gener ation</w>
bo di
4 ,</w>
ogene sis</w>
ur ther
f ar
o red</w>
neg ative</w>
c ros
8 %</w>
lip id</w>
l ed</w>
um -
paclitax el</w>
def ic
volum e</w>
vi r</w>
ent am
disor der</w>
arrhythmi as</w>
P G
u sion,</w>
ox ic</w>
or s,</w>
T reat
. 0
consist ent</w>
(1 0</w>
f et
e di
inf ec
cor tico
in ic</w>
in de
func tional</w>
er s.</w>
ch all
ag l
Q T</w>
l un
t s.</w>
sensi tive</w>
appro ximately</w>
sus cepti
model s</w>
mag ne
resul ting</w>
evalu ation</w>
e p</w>
ur ac
ti l</w>
over all</w>
inc rist
hyperten sion.</w>
hospit al</w>
drug -induced</w>
cyclophosph amide</w>
at e,</w>
repe ated</w>
pa thetic</w>
om e</w>
mort ality</w>
literat ure</w>
wh om</w>
ur b
regi men</w>
recei ve</w>
re duce</w>
nephro tic</w>
ep ti
dex amethas
addi tional</w>
month s.</w>
man age
im ag
es pec
b or
anti psycho
al lo
a vir
ran ial</w>
pen icill
( I
impair ment</w>
espec ially</w>
mg/k g/
deg ree</w>
at e.</w>
ret ur
d g
S er
2 .</w>
ul arly</w>
aspir in</w>
S i
2 00</w>
ris perid
h al
av ail
vis ual</w>
subsequ ent</w>
hepar in</w>
coca ine-induced</w>
con sc
carb am
9 %</w>
us ers</w>
transpl ant</w>
press ed</w>
a de
r o</w>
dose- dependent</w>
b ri
C ardi
( 1</w>
under went</w>
potassi um</w>
post operative</w>
es tim
cy cl
ot rex
cardiomyo pathy</w>
achi e
3 )</w>
opio id</w>
m ut
arrhyth mic</w>
larg e</w>
C )</w>
A R
1 7</w>
ru s</w>
rolim us</w>
ic ul
concl ude</w>
antagonist s</w>
al co
Whe n</w>
8 0</w>
ver apam
thresh old</w>
m ,</w>
patient 's</w>
pa in.</w>
control s.</w>
a ke</w>
y cl
v om
c al</w>
alter ations</w>
acti vi
u tive</w>
s he</w>
or .</w>
mit ochond
progres sive</w>
pro phyl
platele t</w>
ore ,</w>
nec rosis</w>
do pa
4 8</w>
sk in</w>
p ected</w>
ocyt e</w>
clin ically</w>
U R
om orph
h ic
t om
stand ard</w>
memor y</w>
inhibit ors</w>
au th
I m
y ing</w>
micro scop
ex ist
attenu ated</w>
6 ,</w>
un d
suppor t</w>
he dul
chall eng
5 )</w>
D e
pl at
T R
ophyl line</w>
7 %</w>
d en
0. 5</w>
thrombo sis</w>
re current</w>
pre dn
ent .</w>
az ine</w>
( V
te en</w>
su stained</w>
he x
surger y</w>
par kin
comp oun
sp ite</w>
o z
flu oro
feat ures</w>
T )</w>
id al</w>
i.p .)</w>
b one</w>
Tw ent
H e
F urther
use ful</w>
the re
Treat ment</w>
st age</w>
sch iz
mol /
st ron
hippocamp al</w>
cy to
test s</w>
qu anti
con comit
9 0</w>
ta in</w>
initi ation</w>
ent ,</w>
d ine</w>
con sec
cogn itive</w>
am ine-induced</w>
aff ect</w>
Th us,</w>
t am
revie w
grow th</w>
an th
sc hedul
o v
er ing</w>
youn g</w>
anesthe tized</w>
p ic
manage ment</w>
g entam
frequ ent</w>
fibrill ation</w>
arc h</w>
adrenoc ept
o ff
lon g</w>
intra peritone
ut ed</w>
parkin son
nec ess
n ed</w>
intest inal</w>
complete ly</w>
R ec
neuro toxicity</w>
mon o
character ized</w>
F )</w>
rap id</w>
ment .</w>
indic ated</w>
S R
oc lon
ai m</w>
ag ic</w>
tak en</w>
path w
ad riam
ab normal</w>
suc cess
exc retion</w>
di ure
cholin ergic</w>
om e
i atric</w>
aden osine</w>
TI ON
L i
vi a</w>
sti t
perf usion</w>
isol ated</w>
anti depress
W ist
N A
ter min
statis tically</w>
pro ble
id ity</w>
hypoten sive</w>
hear ing</w>
az ole</w>
anti convulsant</w>
anal o
a or
s ),</w>
is ed</w>
cholest er
ac tions</w>
ne ut
f atal</w>
evo ked</w>
epileptic us</w>
clon idine</w>
agl and
- associated</w>
ve .</w>
s core</w>
respectivel y,</w>
pea k</w>
lab oratory</w>
h our</w>
are a</w>
SE :</w>
se g
on e-
7 5</w>
v incrist
man y</w>
as .</w>
Parkinson 's</w>
se m
meta st
immun e</w>
not ed</w>
le ,</w>
gra m</w>
N O
thrombocytopen ia</w>
thec al</w>
oxy gen</w>
neuron al</w>
inter val
f y</w>
common ly</w>
C N
ni qu
maxim um</w>
l .</w>
ho l</w>
det ected</w>
cor related</w>
repor ted.</w>
sp ecti
rever sed</w>
mi x
meth otrex
lat er</w>
er gen
p ap
ob j
ine d.</w>
conduc ted</w>
1 9</w>
ref r
n ine</w>
mon th</w>
inter action</w>
g am
consec utive</w>
viv o</w>
recor ded</w>
un til</w>
neuro path
ly ing</w>
em ergen
( 9
toler ated</w>
s li
oc on
gr ad
di ast
cardi otoxicity</w>
Ne uro
u pt
pilocarp ine-induced</w>
iz ed,</w>
i an</w>
electro cardio
el der
al -
refr act
prob ably</w>
capsa icin</w>
bet a</w>
as e,</w>
al le
I N
kg (-1
id om
ac comp
oph ren
develop ing</w>
C P
ve red</w>
resol ved</w>
headac he</w>
ch arg
ro w</w>
isoproteren ol</w>
inf ants</w>
anim als.</w>
s ing</w>
fentan yl</w>
est ro
canc er.</w>
bupivaca ine</w>
ap pe
th yro
pro m
dist urb
fail ed</w>
car e</w>
ar t
per cent</w>
i ve</w>
ect om
dose .</w>
c r
- like</w>
dop aminergic</w>
w o
subj ect
sel f-
parameter s</w>
on ucle
effect .</w>
ed ly</w>
di ed</w>
rit er
ri bu
re m
rat .</w>
mg/ d
double-bl ind</w>
diagnos ed</w>
UR PO
P URPO
-1 .
m l</w>
m RNA</w>
Clin ical</w>
sym pathetic</w>
con g
block ade</w>
aver age</w>
AI D
tion s,</w>
M )</w>
( mean</w>
seroton in</w>
mechan ical</w>
con si
K -
9 -
under lying</w>
prol act
metabol ic</w>
j ection</w>
b ility</w>
at s</w>
S e
vit ro</w>
PURPO SE:</w>
% ;</w>
nit ric</w>
ischem ia</w>
arrhyth mia</w>
schiz ophren
resist ant</w>
prost agland
mo re,</w>
GAB A
D NA</w>
perio d.</w>
individ u
war far
p ren
o lo
ble ed
sco res</w>
intra ven
di pyri
st op
propran olol</w>
dipyri dam
In tra
2 ).</w>
fe w</w>
ect ing</w>
cl u
alter n
( 5</w>
resist ance</w>
las tic</w>
accomp an
C H
level s.</w>
il l</w>
ide ,</w>
hemorrh age</w>
er b
enc es</w>
di azepam</w>
ac h
S ub
(2 .
pregn anc
ne w
li e
en al</w>
ch ed</w>
wo uld</w>
refle x</w>
no rep
tam oxif
se ,</w>
rec i
del ayed</w>
P R
refract ory</w>
le ar
ap omorph
ag g
1 00
surg ical</w>
t ech
se em
or der</w>
lun g</w>
com pl
E E
) -induced</w>
pop ul
confir med</w>
v es
pre val
per cent
conf idence</w>
chlor ide</w>
ap plic
ance .</w>
rel atively</w>
bil i
al tered</w>
L )</w>
C I</w>
lam iv
anti bodi
0.05 )</w>
y s</w>
ster oid</w>
gast ro
u ter
toler ance</w>
ti s,</w>
ref ore,</w>
nal ox
Wist ar</w>
C D
v ag
s por
Eff ects</w>
ocicep tive</w>
mark edly</w>
lo p</w>
deve lop</w>
(1 )</w>
random ly</w>
patter n</w>
effect s,</w>
diseas e,</w>
8 ,</w>
sup ple
mou se</w>
bil ateral</w>
A s</w>
2 8</w>
2 3
ve hic
stri atal</w>
ru b
h is</w>
diast olic</w>
c riter
b ile</w>
n .</w>
locom otor</w>
reg ul
om eth
be g
n g/
continu ed</w>
p raz
auth ors</w>
ac ce
7 ,</w>
2 5
tri als</w>
ol ar</w>
chol ine</w>
ar ge
0.0 00
side -
s le
partic ularly</w>
Th ir
I )</w>
z e</w>
tw ice</w>
os f
no vel</w>
gen eral</w>
correl ation</w>
8 0
vas odi
obser ved.</w>
n or</w>
hyperal gesi
eth an
diabet es</w>
de spite</w>
II I</w>
prot ection</w>
upt ake</w>
eryth ro
ind ometh
foc al</w>
am ine,</w>
C S
te x</w>
re ly</w>
activi ties</w>
2. 5</w>
valu e</w>
oxid ative</w>
behavi or</w>
Further more,</w>
trem or</w>
st ra
sion s.</w>
potenti ally</w>
ex ac
c ri
an ter
ad mitted</w>
( F
el ic
dyskine si
con sequ
am ine.</w>
activ ity,</w>
ac c
R es
P ,</w>
2 50</w>
pr us
mar row</w>
ful ly</w>
transplant ation</w>
st ate</w>
recomm end
ap paren
T E
requ ir
ne on
fol d</w>
analgesi c</w>
G F
D A</w>
inde x</w>
examin ation</w>
child ren
y r
prov ide</w>
intra thecal</w>
concomit ant</w>
us ually</w>
st re
pl ay</w>
high -
exc it
est er
dis charg
da il
t s,</w>
pheny to
otrop ic</w>
inten sity</w>
t le</w>
rap id
pre vention</w>
pre treated</w>
p as
ic ,</w>
at tri
50 %</w>
ster one</w>
glomer ul
cor tical</w>
cong estive</w>
2 4
subst anti
occur ring</w>
en e</w>
demonst rate</w>
de d.</w>
u it
physi ological</w>
ing es
in suffici
impa ired</w>
et ine</w>
benz odi
i um</w>
i es.</w>
wat er</w>
gener alized</w>
appro pri
A S
0 00</w>
su per
reci pi
phen obarbit
n =
hemo dynamic</w>
ffe red</w>
progres sion</w>
ineph r
ex tr
S he</w>
P er
se arch</w>
ne x
docum ented</w>
ap op
cor tex</w>
adren aline</w>
as th
5- F
metabol it
neurolog ical</w>
imag ing</w>
doxorub ic
adju st
S H
psych iatric</w>
ne ed</w>
exhib ited</w>
em ia,</w>
A m
tempor al</w>
outcom e</w>
oni um</w>
channe l</w>
caffe ine</w>
block ing</w>
thal am
mi gra
bas al</w>
st able</w>
neurolog ic</w>
iz e</w>
hypo kal
attri but
amiodar one</w>
Q T
vir al</w>
thir d</w>
su m
al s,</w>
SI G
r al</w>
prot oc
oc or
m as
. 00
p ub
mol ec
lif er
ide .</w>
hypo thesis</w>
E )</w>
o side</w>
m ade</w>
g est
ex cep
elev ation</w>
concl uded</w>
a -
per oxid
main tained</w>
2 2</w>
wide ly</w>
im pl
cas es.</w>
vol un
my oclon
metabol ism</w>
ep inephrine</w>
am ne
C Y
nitro prus
7 0</w>
reg ar
monit ored</w>
methyl -
ha em
a di
O R
In c
pro lifer
o ti
mid azol
wh ite</w>
symptom atic</w>
sti ll</w>
oly sis</w>
da y,</w>
at ro
R enal</w>
tech niqu
ol amine</w>
hem olytic</w>
rat e,</w>
pre -
p ose</w>
ocyt es</w>
nec ro
anti coag
F or</w>
E P
DE SIG
obj ective</w>
concl usion,</w>
Twent y-
urac il</w>
proper ties</w>
pro pi
n at
low -
co hor
am oun
1 .</w>
0.00 1).</w>
on ce</w>
am pl
in si
immun os
encephalo pathy</w>
elder ly</w>
tre at</w>
mat er
l ast</w>
decreas es</w>
car ri
vi rus</w>
stri at
rhe um
mus cular</w>
es s.</w>
disorder s</w>
di et
con duction</w>
cess ation</w>
sens ory</w>
se t
meth ad
hemorrh agic</w>
graph y</w>
an ,</w>
F our</w>
z ol
at tac
anti oxid
E n
ti ally</w>
ribu tion</w>
ne ed
id ate</w>
angiotens in</w>
y :</w>
le ad</w>
ind ,</w>
ate d,</w>
haloperid ol-induced</w>
fib ro
ep id
em bol
car bo
acti n</w>
te tra
stro ke</w>
s ince</w>
rop en
perform ance</w>
ot er
mitochond rial</w>
main ten
anti bio
B ec
5 00</w>
low ing</w>
st on
sensi tiz
s oci
reg ulation</w>
di z
bi ochemical</w>
accompan ied</w>
ab use</w>
y mptom
pharmaco kine
partic ip
in a</w>
cont ent</w>
5 %)</w>
t ure</w>
p epti
metast atic</w>
le y</w>
is h</w>
func tion,</w>
discontinu ed</w>
as es</w>
year s.</w>
ul e</w>
th reat
patient .</w>
p u
do but
H -
om a.</w>
oc ular</w>
epilep sy</w>
bol us</w>
H e</w>
mo dul
ine- treated</w>
defici ency</w>
z in
ket amine</w>
induc es</w>
hypoten sion.</w>
clo zapine</w>
verapam il</w>
se par
gen ous</w>
est radi
( p
rel ap
flu id</w>
fic ial</w>
em br
compar able</w>
E D
D 2</w>
ta ke</w>
repor t.</w>
random ized,</w>
gen e
b ic
6 )</w>
4 )</w>
j unc
high ly</w>
hyper activity</w>
discus sed.</w>
convul sive</w>
v ast
r ho
pr ag
org an
malign ant</w>
ill ary</w>
en al
def ined</w>
tachy cardia
pa in,</w>
maxim al</w>
fail ure,</w>
e y
clear ance</w>
apop to
C R
retur ned</w>
pub l
ou ab
S prag
D aw
3 5</w>
pressu re,</w>
p t</w>
symptom s.</w>
s. c
pro spective</w>
in te
dexamethas one</w>
d o</w>
Bec ause</w>
( 95%</w>
pre par
lim b
agonist s</w>
achie ved</w>
en .</w>
dog s.</w>
cle s</w>
ram idal</w>
prostagland in</w>
m ia.</w>
in dependent</w>
dep le
ca the
aut o
Daw ley</w>
DESIG N
3 0
u e-
toxic ity,</w>
star ting</w>
s ite</w>
persist ent</w>
or -
om en
gr af
coun t</w>
N MD
B P</w>
is tic</w>
hy dr
2 3</w>
) )</w>
prof ile</w>
infu sion.</w>
immunos up
hormon e</w>
di et</w>
contrib ute</w>
c h</w>
se .</w>
rapid ly</w>
preval ence</w>
pre ci
plas tic</w>
os in</w>
der iv
ab o
M R
n if
mo ve
membran e</w>
lim ited</w>
iltr ation</w>
divid ed</w>
Eff ect</w>
An ti
2 6</w>
vas o
syn ap
stre pt
injec tion.</w>
hepat oc
G )</w>
D ru
1. 5</w>
t ur
rib avir
ox i
model .</w>
b ar
ati c
appe ar</w>
tum ors</w>
si mul
remain s</w>
ph al
l ate</w>
in toxic
pharmac ological</w>
le ph
comp on
ax is</w>
w a
risperid one</w>
pro duction</w>
mainten ance</w>
inf used</w>
glutam ate</w>
aor tic</w>
star ted</w>
nitro glycer
inflam m
cis e</w>
ce f
cat ech
b rom
azep am
assess ment</w>
act ing</w>
comple x</w>
as c
DESIGN :</w>
the si
sed ation</w>
mon ke
intraven ously</w>
chang ed</w>
appropri ate</w>
A ,</w>
we ak
or ation</w>
nucle us</w>
o ver,</w>
idom ide</w>
gen e</w>
block ed</w>
M y
st ere
k .</w>
f rac
A T</w>
one -induced</w>
group s,</w>
pit uit
neut ropen
my c
cysti tis</w>
con sum
a un
4 5</w>
4 4</w>
ra m</w>
placebo -
or ally</w>
fem al
dom in
day s,</w>
cor ding</w>
P .</w>
s '</w>
meth amphetamine</w>
inf ection</w>
antagonist ,</w>
w er</w>
om as</w>
g al
di alysis</w>
cyclo spor
consc ious</w>
arc in
uro myc
the ophylline</w>
par t</w>
methotrex ate</w>
in sul
anti arrhythmic</w>
threat ening</w>
pe di
neur al</w>
in st
carcin oma</w>
0.0 1).</w>
surger y.</w>
mic e,</w>
long er</w>
inc id
dose ,</w>
bec ame</w>
F ol
si g
om et
kin ase</w>
if osf
S C
th io
struct ural</w>
p al
m u
inhibit ory</w>
S .</w>
E i
meth o
day )</w>
Hy per
volun te
p s</w>
lox acin</w>
anter ior</w>
reg res
qu ine</w>
pur pose</w>
os in
m ia,</w>
lif e-
g li
condi tions</w>
avail able</w>
Sprag ue-
us ual</w>
supple ment
phen omen
double-bl ind,</w>
cis platin</w>
b re
al one.</w>
M ore
E NT
tamoxif en</w>
rheum at
path ogenesis</w>
ma .</w>
it al</w>
immedi ately</w>
descri be
am ine-
U n
well -
seizures ,</w>
res er
pro por
indic ating</w>
experi ence</w>
cyclophosph amide
bet ter</w>
V )</w>
2 ,
carbam azepine</w>
b ul
antibodi es</w>
W h
PA TI
lo fen
de n</w>
ance ,</w>
Sprague- Dawley</w>
S cal
S -
7 )</w>
ro tox
ran s
point es</w>
B e
week ly</w>
st -
p ut
ol /
log ical</w>
is e</w>
emergen cy</w>
al b
GAB A</w>
3 2</w>
3 00</w>
suscepti bility</w>
otoxic ity.</w>
cor rec
C o
wor sen
saf e</w>
presc ribed</w>
ox in</w>
o ther
long -
lid oca
lat eral</w>
invol vement</w>
gastro intestinal</w>
consi der
compoun ds</w>
M P
2 /
possib ility</w>
amin onucle
PATI ENT
HB V</w>
sup pression</w>
literat ure.</w>
lead ing</w>
l act
haloth ane</w>
gam ma
characteris tics</w>
possib ly</w>
or th
or b
nephro pathy</w>
main ly</w>
li g
el ec
C A</w>
rati o
im b
fr action</w>
depend ently</w>
compar e</w>
as ,</w>
analy zed</w>
adrenocept or</w>
throu gh
stop p
ro x
respon sible</w>
n s</w>
levo dopa</w>
high est</w>
dyskine sia</w>
Ad minist
ic ardi
exac erb
es sen
r ation</w>
min ant</w>
le th
id s</w>
ex tent</w>
c ed</w>
The refore,</w>
test ing</w>
poin t</w>
min ,</w>
ex amine</w>
c he
aun dic
anxi ety</w>
S M
R ats</w>
More over,</w>
L ,</w>
H D
rec ent</w>
r as
prom ot
ph asi
pedi atric</w>
ocor tico
inf orm
hy pe
ere bral</w>
U /
C .</w>
4 00</w>
su d
rat e
p uromyc
lif e</w>
fi el
em b
av oid
appear ance</w>
ant in
a sia</w>
S ince</w>
up on</w>
th us</w>
reco vered</w>
pos ed</w>
norep inephrine</w>
nause a</w>
h ,</w>
fet al</w>
dys function.</w>
applic ation</w>
P las
sm all
le dg
P D
5 ).</w>
v an
ol ar
gener ally</w>
con ven
at or</w>
F ive</w>
(1 00</w>
y )</w>
sh oc
pop ulation</w>
oxy gen
op tic</w>
N G
0. 1</w>
t on
recommend ed</w>
pro vid
pr amine</w>
it ation</w>
vasodi lat
ur ic</w>
mat ure</w>
in ing</w>
en ro
be ll
administr ation,</w>
C -
reduc ing</w>
p ect
injur y.</w>
ic k
e ly</w>
I F
( 2</w>
system .</w>
rec ently</w>
pic rotox
ot en
magne si
ev id
di min
condi tion</w>
stron g
neuro pathy.</w>
e mo
an other</w>
L /
3 6</w>
3 .</w>
3 ,
- dependent</w>
t or
rang e,</w>
prolong ation</w>
neph ritis</w>
le g
f at
equ al</w>
bleed ing</w>
V PA</w>
on s</w>
nif edi
includ e</w>
fic ation</w>
endo genous</w>
amin oph
( n=
si m
sex ual</w>
ograph ic</w>
antagon ized</w>
A mon
0. 6
use ,</w>
spont aneously</w>
pro ca
occur s</w>
know ledg
dopa -induced</w>
condi tion
cl ero
ari ly</w>
anth rac
aminoph en</w>
C ocaine</w>
ser ies</w>
cl assi
P D</w>
transplant ation.</w>
ti le</w>
studi ed.</w>
sec retion</w>
phosph ate</w>
oc ript
lit tle</w>
level s,</w>
ic s</w>
alco hol</w>
2 7</w>
y si
steroid al</w>
seem s</w>
r ad
o ur
iti s.</w>
f ron
f low
er ior</w>
enal ap
thi az
rat e.</w>
pro specti
minim al</w>
intrac ranial</w>
il d</w>
excep t</w>
e jection</w>
apparen t</w>
ad ol
EC G</w>
Amon g</w>
uc in
ot oc
kg -1</w>
fac il
ear li
anti- inflammatory</w>
0 %)</w>
on al</w>
gly co
ence ,</w>
elec tr
contrac ep
cere bro
acet am
3 %)</w>
warfar in</w>
pro xim
ol an
ev ent</w>
cholester ol</w>
T -
NMD A</w>
2 9
v als</w>
rheumat oid</w>
oph ysi
month s,</w>
mo d
low -dose</w>
h all
g a
da y.</w>
ch o
ab ine</w>
0. 5
ven til
endo thelial</w>
cas es,</w>
cal cul
abo ve</w>
I ,</w>
1 /
year s,</w>
typ ical</w>
l ine
gran ulo
glut athi
epid ural</w>
EE G</w>
D es
wh ere</w>
ur g
sc ale</w>
phenyto in</w>
ot oxic</w>
hippocamp us</w>
S N
flu ox
d ent
c u
N O</w>
pu t</w>
oph il
mat ched</w>
ens ity</w>
I -
sc re
predn isol
men ing
medic ations</w>
lim iting</w>
fib rosis</w>
f am
drug s,</w>
deter i
coca ine.</w>
brady cardia
at yp
S im
simul t
sc al
ro ut
review ed</w>
puromyc in</w>
ob struc
min .</w>
l -
inter vals</w>
hyperten sion,</w>
hyper sensitivity</w>
e )</w>
deli ri
as ed</w>
w ill</w>
up per</w>
typ es</w>
s ac
prop yl
on ate</w>
ocardi al</w>
j aundic
ine mia</w>
in take</w>
identi fy</w>
ha ving</w>
g ang
dobut amine</w>
ap y
ad dic
abdom inal</w>
Plas ma</w>
8 )</w>
trans por
through out</w>
syn thesis</w>
ra ther</w>
adriam ycin</w>
ade qu
7 2</w>
tre mor
si d
re mia</w>
r ic
p .
k g/
indometh acin</w>
hypoten sion,</w>
fo ur
cor tis
A g
10 -
un i
s al</w>
r ab
quanti t
predic t
mus car
microgram s</w>
mg/kg ),</w>
mater nal</w>
li ght</w>
k ind
a reas</w>
ures .</w>
ur ia,</w>
sup pressed</w>
neurolep tic</w>
it h</w>
ful minant</w>
establ ished</w>
er s,</w>
to ge
parkinson ian</w>
is m.</w>
cohor t</w>
can n
antipsycho tic</w>
a emia</w>
OBJECTIVE S:</w>
produc es</w>
p lo
myo pathy</w>
meth od</w>
as signed</w>
H i
rat ing</w>
last ing</w>
i.v .)</w>
b asis</w>
as part
ac cording</w>
A .</w>
1 %)</w>
0. 9
rel ax
present ing</w>
om al</w>
drug ,</w>
de signed</w>
cir cul
arter i
anal gesia</w>
W ith</w>
U S
Administ ration</w>
tr ic
path y,</w>
impro ve</w>
ap pl
2 ),</w>
y g
ti vely</w>
retro spective</w>
requ i
individ ual</w>
ence .</w>
con cer
L .</w>
tac rolimus</w>
sit es</w>
re ten
lab el
individu als</w>
chem ical</w>
cell ular</w>
(A B
pituit ary</w>
oter icin</w>
ol der</w>
ne um
h om
as e.</w>
anesthe tic</w>
6 5</w>
to -
ret ino
re lev
o t</w>
life- threatening</w>
exist ing</w>
CA SE</w>
4 .</w>
un treated</w>
thrombo tic</w>
t a</w>
inf ected</w>
hum an
ca us
S ev
prol actin</w>
lamiv udine</w>
glob in</w>
dipyridam ole</w>
de oxy
ar rest</w>
' -
sup pres
nalox one</w>
h r</w>
go od</w>
describe d.</w>
cell s.</w>
pheny leph
percent age</w>
path ophysi
ma in</w>
impl ant
fer ase</w>
do w
chemo therapy.</w>
tic s.</w>
recept ors.</w>
proxim al</w>
on in</w>
gluc ose</w>
gast ric</w>
gamma -
ethan ol</w>
ate -
apy ramidal</w>
ame li
ac qu
AT P
t ex
se ly</w>
gentam icin</w>
es sive</w>
en ,</w>
af ter
ac tic</w>
L I
2 9</w>
0. 7
oc ca
m mol/
lo ad
invol ving</w>
hyper prolact
det ect
al ter</w>
agent s.</w>
Sev ere</w>
PG E
C T
( 3</w>
tri al.</w>
treat ments</w>
se ud
ri tis.</w>
requir ing</w>
necess ary</w>
infarc tion.</w>
in ation</w>
f ore
elic ited</w>
cy cle</w>
acet aminophen</w>
D S)</w>
1 50</w>
war d</w>
vascul itis</w>
respon ding</w>
mm Hg
ment ,</w>
le -
l eng
headac he
experim ents</w>
ce mia</w>
AC T</w>
week s,</w>
subsequ ently</w>
propo fol
posi tion</w>
per for
o .</w>
inges tion</w>
cir rho
atyp ical</w>
abdom y
Ser um</w>
0.00 1)</w>
valpro ic</w>
se ve
s os
re curren
muscar inic</w>
criter ia</w>
conven tional</w>
Me an</w>
region al</w>
preci pit
meas ures</w>
diff er</w>
com a</w>
co -
aw are</w>
anaesthe sia</w>
al op
Inc reas
4 %)</w>
2 4-
( group</w>
uro sem
sa des</w>
penicill amine</w>
ne o
me dul
m s.</w>
id ov
hall ucin
conver ting</w>
un it</w>
til ity</w>
patient ,</w>
midazol am</w>
kg )</w>
e me
abol ished</w>
(P <
y clo
sli gh
reduc es</w>
prev ent
oz otoc
gang li
cere bell
cardiomyo pathy.</w>
brom ocript
as al</w>
X -
3 9
stric tion</w>
s amp
region s</w>
or ity</w>
on .</w>
oc cl
anti body</w>
ti n</w>
there fore</w>
the m</w>
sus pected</w>
ri se</w>
qu es
fac e</w>
exer cise</w>
depress ed</w>
de s
ant s.</w>
7 %)</w>
19 8
0. 8
( 0.0
vaso press
osin ophil
i ved</w>
end -
contrib ut
cholest asis</w>
au g
allo dyn
2 %)</w>
rab b
nephro toxicity</w>
lac k</w>
episo de</w>
ent ly,</w>
re mo
on -
muc h</w>
migra ine</w>
cum ulation</w>
I NT
D op
Ad verse</w>
ti az
or i
mm Hg</w>
k ,</w>
cl ass</w>
children .</w>
art an</w>
ant ly</w>
ST R
On ly</w>
C M
3 ).</w>
0.0 1)</w>
ur ia.</w>
t as
spec ific
sp as
si a,</w>
response .</w>
ors ade</w>
o si
methad one</w>
iz ing</w>
depend ence</w>
deg re
ar m</w>
toxic ities</w>
pit e</w>
leuk emia</w>
hy d
hepatoc ellular</w>
comp ound</w>
anesthe sia.</w>
Des pite</w>
6 %)</w>
- -
sub cutaneous</w>
medul l
lat ency</w>
g ue</w>
H IV
H )</w>
Fol lowing</w>
0. 2</w>
vincrist ine</w>
sle ep</w>
s ar
rel ation</w>
om ycin</w>
ic -
he l
g re
fen flur
end ing</w>
1. 0</w>
( i.
p ron
n er</w>
magnesi um</w>
h und
cap top
b ir
R -
pressu re.</w>
ml /
lat er,</w>
glob ul
enzym es</w>
altern ative</w>
(2 0</w>
( 50</w>
top ical</w>
r in
pul se</w>
physi cal</w>
observ ation</w>
isoproteren ol-induced</w>
ine )</w>
diz zin
direc tly</w>
bu propi
9 9
os mol
m L</w>
fe rence</w>
estim ated</w>
ep inephr
cholest atic</w>
all y.</w>
A r
ma ,</w>
initi ated</w>
f av
dose s.</w>
diure tic</w>
desc rib
cor tex
al k
The y</w>
A s
1 2-
sud den</w>
steroid s</w>
sion s,</w>
mus t</w>
intraperitone al</w>
immun ore
b ur
aspart ate</w>
5- fluoro
vi ous</w>
ribavir in</w>
perio d,</w>
or e</w>
mix ed</w>
hist ological</w>
g ,</w>
dist ribution</w>
diff icul
arg inine</w>
Com par
(3 )</w>
need ed</w>
me tr
know n.</w>
inter fer
cy cles</w>
carbo platin</w>
ag e-
Cardi ac</w>
A P
2 6
tr as
suc cin
pre domin
hypertroph y</w>
doxorub icin-induced</w>
dos ing</w>
dam age.</w>
challeng e</w>
Pre treatment</w>
CY P
CI ,</w>
3 1</w>
( i
w all</w>
vom it
trans f
stro k
rig idity</w>
n oc
f ed</w>
antioxid ant</w>
al ol</w>
adren al
ac t</w>
ab le.</w>
w ay</w>
valpro ate</w>
si l
iso flurane</w>
is ch
investig ation</w>
il .</w>
i.p .
cros s-
cour ses</w>
carri ed</w>
L e
I g
st en
regres sion</w>
reac tive</w>
ot om
och rom
iti es.</w>
defic its</w>
cor d</w>
at a</w>
an o
amph otericin</w>
C ,</w>
trac t</w>
synap tic</w>
pro mis
f urosem
es )</w>
epilep sy.</w>
d ensity</w>
cul t
Si x</w>
2 7
vom iting</w>
ure a</w>
thresh ol
regimen s</w>
me ti
S P
ro n</w>
r y</w>
or ig
observ ations</w>
mg/ day</w>
ke le
inhib it</w>
implic ated</w>
hund red</w>
gen etic</w>
fi t</w>
d )</w>
ac cumulation</w>
U D
Q u
z idov
thi op
subject s.</w>
strept ozotoc
pro maz
physi ci
n a</w>
hyper cal
func tion
fron tal</w>
ent er
consist ed</w>
[ 3
s wit
hepati tis.</w>
find ing</w>
d ors
bene ficial</w>
ampl it
STR ACT</w>
C T</w>
5 7
ron ch
res c
recogn ized</w>
op i
on g
normal .</w>
n one</w>
kg(-1 )</w>
i b
el im
e -induced</w>
an .</w>
W OR
TE D</w>
PA N</w>
E l
D o
(+ )-
thal idomide</w>
strong ly</w>
resol ution</w>
regar ding</w>
prof en</w>
par tially</w>
norm oten
complic ated</w>
bor n</w>
block er</w>
WOR DS)</w>
UN CA
UNCA TED</w>
TR UNCATED</w>
F if
(AB STRACT</w>
un it
syn cop
subst ance</w>
publ ished</w>
ne i
ia sis</w>
glutathi one</w>
di sp
de part
MT X</w>
F -
vas ocon
ron ic</w>
pa rox
od ds</w>
molec ular</w>
gluc ocortico
extr apyramidal</w>
ev er</w>
2 8
sy ,</w>
spec tr
place ment</w>
dyskinesi as</w>
diagnos tic</w>
cl er
ad ine</w>
L V</w>
In ter
2 5-
radi o
ra rely</w>
om ic</w>
em at
di azepam
al bu
tiv en
test .</w>
shor t</w>
remain ing</w>
over dose</w>
nitroprus side</w>
micro g</w>
inform ation</w>
i.p .</w>
gra v
ca ref
W ith
Scal e</w>
H ist
sligh tly</w>
sel ected</w>
placebo- controlled</w>
olog ically</w>
intr am
clon id
aminonucle oside</w>
al g
TION :</w>
pro vi
pre ce
placebo .</w>
on ,</w>
e osinophil
Wh ile</w>
ve loc
tic ent
sp i
pres ents</w>
pregnanc y</w>
pent obarbit
nei ther</w>
min )</w>
infu sions</w>
f all</w>
activ ated</w>
0. 3</w>
( range</w>
v ant</w>
syn th
som n
re fl
metabolit es</w>
atro pine</w>
ar tic
success fully</w>
ici ans</w>
di an</w>
cer tain</w>
a ph
dil tiaz
cl onic</w>
ca using</w>
appl ied</w>
amoun t</w>
O ther</w>
C l
si ze</w>
par acetam
ot rans
neon atal</w>
l ic
il ateral</w>
hist opath
gu an
b ronch
adol es
L D
C or
4 0
4 ).</w>
y ;</w>
se s.</w>
oc arcin
manifest ations</w>
l er
g y
extrac t</w>
ex trem
ex pres
anticoag ul
amne sia</w>
al ong</w>
al most</w>
I T
-1 -
pro fi
potenti ated</w>
pl asia</w>
or rh
move ments</w>
fentan il</w>
estro gen</w>
ch ic
ameli or
MA P</w>
un usual</w>
sensitiz ation</w>
rh abdomy
it ory</w>
in ning</w>
deriv ati
3 3</w>
( 3.
samp les</w>
rever sal</w>
pron oun
par alle
o vari
lox ac
i dis
ch ar
O )</w>
- type</w>
vast atin</w>
um -induced</w>
re lie
prophyl axis</w>
pr acti
nause a,</w>
find ing
fi x
de generation</w>
d on
attribut ed</w>
T H</w>
M eth
B y</w>
ymptom atic</w>
respon ded</w>
protein s</w>
open -
lo cal
im i
G lu
Ch ronic</w>
3 7</w>
1 20</w>
ri f
p neum
n ociceptive</w>
follow- up
comple x
a )</w>
H ep
respectively ).</w>
injec tion,</w>
flu o
c .
bili ary</w>
ad ded</w>
symptom s,</w>
poly morph
mag nit
initi ally</w>
creat ine</w>
ap lastic</w>
S ign
M A</w>
I .</w>
CN S</w>
ul tras
ta il
studi es.</w>
pregn ant</w>
ost e
nifedi pine</w>
g er</w>
anti hypertensive</w>
S ,</w>
vari ety</w>
trans mission</w>
tem per
si vely</w>
inter mit
h .</w>
facil it
estradi ol</w>
essen tial</w>
dors al</w>
death .</w>
tri gg
t onic</w>
st o
phenobarbit al</w>
n ess,</w>
my el
mg )</w>
metabol ite</w>
maj ority</w>
f en</w>
b aro
IS C
A b
9 ,</w>
res on
ob ut
li po
le sion</w>
impro ve
import ance</w>
hydro chloride</w>
di ar
der ived</w>
comple ted</w>
a im
ISC US
I N</w>
F or
D ISCUS
5 5</w>
vie w</w>
vehic le</w>
treat ing</w>
stere otyp
rou s</w>
re verse</w>
pac t</w>
org an</w>
oni az
od -
is oniaz
extrac ellular</w>
exten sive</w>
di pine</w>
depres sive</w>
cathe ter
arac h
aden ocarcin
Y :</w>
1. 0
st rate
regi on</w>
prevent ing</w>
prednisol one</w>
pi ri
phosph at
per son
out put</w>
inhibit or,</w>
i bu
hemat ologic</w>
degre es</w>
cis plat
c -
bl ast
am mon
G -
F urther</w>
DISCUS SION
wh ose</w>
st in
shor t
path ological</w>
os pas
l up
ch rom
bene fit</w>
alb um
agent ,</w>
adju vant</w>
a vir</w>
M MA
ve -
test o
op tim
is ,</w>
equ i
det ection</w>
dent ate</w>
c ou
P ost
3 4</w>
thou ght</w>
reson ance</w>
plas mic</w>
pan ic</w>
op en</w>
on at
mg/kg ).</w>
he ad</w>
epi thelial</w>
drug -
capsa icin-induced</w>
b al
as e-
arrhythmi as.</w>
D is
B )</w>
t in
su ffered</w>
seg ment</w>
p id
open ia</w>
meas ure</w>
li ver
hepat otoxicity</w>
g em
enh ance
enceph al
dy ston
R A</w>
DISCUSSION :</w>
AD R</w>
0. 4
th at
sp ir
proc es
inten sive</w>
insuffici ency</w>
in es</w>
i onic</w>
fiel d</w>
experim ent
evalu able</w>
dist inc
St ud
Res ul
P C
AC E</w>
8 %)</w>
( 50
temper at
pronoun ced</w>
po or</w>
os cop
muc os
mg ,</w>
earli er</w>
a ir
U sing</w>
B lo
) /
tiven ess</w>
re mission</w>
nor adrenaline</w>
n -
mo vement</w>
induc ing</w>
g all
fac ial</w>
cl ar
catech ol
adequ ate</w>
T TI
SE TTI
F K
F .</w>
t y
reac h
o ventricular</w>
mpt om</w>
e ph
def ects</w>
at roph
anim als,</w>
a fferen
v ent
t orsade</w>
revie we
provid ed</w>
pre mature</w>
pi de
pepti de</w>
min or</w>
li th
l an
in tro
] ,</w>
S yst
3- year-old</w>
succin yl
mor b
hemo globin</w>
bar ri
b us
ation -
ab le
Thir ty-
SETTI NG
u ti
quin ol
prim arily</w>
enro lled</w>
electro n</w>
e :</w>
dig oxin</w>
curren tly</w>
consum ption</w>
M ost</w>
year s)</w>
ti d</w>
sol ution</w>
paclitax el
capsa ic
cap ac
apomorph ine</w>
anthrac ycl
ad mis
Sim il
SU RE
SU MMA
SUMMA R
R ,</w>
H ear
20 -
yl -
y pt
wa ve</w>
ru pt
pent yl
p on
log ic</w>
loc ated</w>
lo b
clin ic
cler osis</w>
beg inning</w>
anti epileptic</w>
acce ler
Resul ts</w>
AI M
ve in</w>
tic s,</w>
syndrome ,</w>
provi des</w>
mg .
differen tial</w>
ang ina</w>
alco h
adjust ed</w>
synth ase</w>
ros s</w>
q /
opath ic</w>
magne tic</w>
ex cl
enalap ril</w>
day s)</w>
benzodi azepine</w>
acetyl choline</w>
H ]
D ata</w>
5 .</w>
3 6
( AC
sulf ate</w>
rem if
pres sive</w>
pa inf
p olar</w>
mo ther
measure ments</w>
ifosf amide</w>
embr y
disorder .</w>
dic lofen
ce .</w>
c ulo
b en
amphet amine-induced</w>
adul ts</w>
R S</w>
ME A
Ad di
( range,</w>
toge ther</w>
side- effects</w>
rif amp
recipi ents</w>
re tic
quantit ative</w>
predn is
one ph
ch ild</w>
cann ab
T N
P <
MEA SURE
H .</w>
tub ul
re -
physi ologic</w>
p seud
occl usion</w>
man ner
magnit ude</w>
l )</w>
ic ular</w>
electr ical</w>
echocardi ography</w>
amin otrans
acce pt
3 8</w>
ul monary</w>
tac t</w>
t oc
sur face</w>
sion al</w>
reten tion</w>
mark er</w>
limb ic</w>
in ated</w>
human s.</w>
h and,</w>
es cal
differen ti
di ethyl
complic ations.</w>
atten tion</w>
athi op
angio edema</w>
Blo od</w>
5- year-old</w>
ve si
use d.</w>
relev ant</w>
pren atal</w>
mul ticent
le pt
interval ,</w>
im pact</w>
describ es</w>
ci meti
chloro quine</w>
c. v
be at
atri oventricular</w>
at er
N one</w>
5 4</w>
u nex
oc lop
embol ism</w>
de hydro
cal c
arth ritis</w>
anti gen</w>
an emia.</w>
20 %</w>
( N</w>
toler ability</w>
ter at
sul ph
pl ayed</w>
oti de</w>
kele tal</w>
con st
amin es</w>
-1 ,</w>
( MA
tig mine</w>
lo be</w>
lin ked</w>
ith rom
in tact</w>
gram s</w>
g s</w>
cri tical</w>
all ,</w>
ad mission</w>
a k</w>
SETTING :</w>
S D
9 %)</w>
4 2</w>
s pre
perio ds</w>
levo dopa-induced</w>
leth al</w>
le b
incl u
analy sis.</w>
agonist ,</w>
SUMMAR Y:</w>
P /
D ox
st abil
recor d
radi ation</w>
prob able</w>
ophyl l
o w
indic ates</w>
in tub
hospit al
hist amine</w>
cle ar</w>
bi polar</w>
be lie
ac tion.</w>
Si x
M P</w>
M I</w>
, 000</w>
ye t</w>
y s
tub er
ren in</w>
prog ester
pre disp
pentyl ene
olan zapine</w>
dr in
de gener
arge t</w>
antidepress ant</w>
. (ABSTRACT</w>
sup ra
press or</w>
immedi ate</w>
enc y.</w>
electro ly
di aly
de ,</w>
chang es.</w>
bupropi on</w>
van com
set t
rest ing</w>
reg ular</w>
proc ess</w>
pneum on
persist ed</w>
non steroidal</w>
medi ate</w>
fir st-
f il
et om
a ud
X )</w>
Sign ific
tor sades</w>
t arget</w>
refle x
recurren ce</w>
lear ning</w>
inflamm ation</w>
hist or
g ir
f asc
3 0-
10 %</w>
success ful</w>
m E
larg er</w>
idi opathic</w>
hour s.</w>
ectom y</w>
at ors</w>
ab les</w>
a qu
Intra venous</w>
ATP ase</w>
5 2</w>
withdraw al.</w>
studi es,</w>
per icardi
nitroglycer in</w>
hypokal emia</w>
hypo thesi
dose s,</w>
psycho tic</w>
produc ing</w>
painf ul</w>
op o
modi fied</w>
malign anc
li gi
l arge
cardi otoxicity.</w>
ap ne
C C
4 8
3 7
1 2.
0. 4</w>
w ide</w>
ul f
ther mia</w>
ri m
rhyth m</w>
protoc ol</w>
pentylene tetra
m ass</w>
intermit tent</w>
ine ster
in i
id o
hear ts</w>
fluox etine</w>
dimin ished</w>
co lo
chlor promaz
bili rub
ab stin
a sive</w>
Pre vious</w>
Ph ase</w>
P E
H IV</w>
Dru g</w>
0 )</w>
stimul ated</w>
propran olo
min ute</w>
l ing</w>
infu sion,</w>
electrocardio graphic</w>
deter m
agent .</w>
adriam yc
CS F</w>
= 0.0
wor k</w>
ul ar
ti es.</w>
shor ten
port al</w>
outcom es</w>
neutropen ia</w>
n ar
level .</w>
knowledg e,</w>
in ity</w>
identi fi
fat ty</w>
f el
er ous</w>
deliri um</w>
ane ur
R B
worsen ing</w>
su peri
schedul e</w>
reduc tions</w>
pres um
normoten sive</w>
mas sive</w>
lo fen</w>
il ,</w>
effec tiveness</w>
di hydro
Se ver
9 )</w>
1 1
( 30</w>
show s</w>
sev o
lo we
in- treated</w>
d ram
bromocript ine</w>
A p
4 50</w>
weigh t,</w>
sal t</w>
re sid
p -
normal ized</w>
amino phen
val v
super oxide</w>
ris ks</w>
meth yl</w>
globul in</w>
g ab
exc essive</w>
eti n</w>
estro gen
dist al</w>
d one</w>
biop si
benzodi azep
ac ut
L ong
A ),</w>
3 8
vac u
re stric
re li
orub icin</w>
intram us
i me
ha emo
control .</w>
at ax
ar d
apopto sis</w>
agg res
V T</w>
Ph en
O ver
C s
4- year-old</w>
(2 -
yl ate</w>
shoc k</w>
poin ts</w>
plac ed</w>
op ic</w>
li gh
enhance ment</w>
dis appeared</w>
det om
clo zap
channe l
blo od-
6- year-old</w>
5-F U</w>
time ,</w>
striat um</w>
stit ution</w>
peroxid ation</w>
ost atic</w>
n ,</w>
m um
kidne ys</w>
h r
et ax
catalep tic</w>
M ale</w>
M B
FK 50
u st
sens or
proca in
on omic</w>
o in
nephro sis</w>
mort al
me ans</w>
l ay
intrac erebral</w>
hal f</w>
e rec
dose- related</w>
de ep</w>
de .</w>
chloro thiaz
bri e
as ymptomatic</w>
S even</w>
L- arginine</w>
D H
7- year-old</w>
stand ing</w>
separ ate</w>
response ,</w>
ox idi
oc al</w>
neuropath ic</w>
lead s</w>
l is
hyp onat
heal th</w>
ex pressed</w>
ate -induced</w>
ast ro
ass ay</w>
a ther
E v
6 00</w>
5-H T</w>
- positive</w>
p um
o sis.</w>
me detom
ind in
in sti
ec oxi
disorder s.</w>
catalep sy.</w>
bra in.</w>
an ine</w>
Se iz
I L
G l
Con tro
A /
6 .</w>
ul ated</w>
tw o-
ref er
mono therapy</w>
log y</w>
jaundic e</w>
inter actions</w>
il i
gran ule</w>
form s</w>
electro encephalo
e ment</w>
aug ment
ath yro
3 9</w>
1 1.
tran sc
that ,</w>
thalam ic</w>
tachycardia .</w>
respon si
pro found</w>
ouab ain</w>
ol -
o k</w>
le d,</w>
g )</w>
fib ers</w>
fib er</w>
fi br
ere bro
epi rub
e .,</w>
chol inester
bac ter
PATIENT S</w>
El ectro
A Z
tri glycer
te d,</w>
t ob
stron g</w>
reviewe d.</w>
ren t</w>
reco ver
perfor me
pathw ay</w>
ill ed</w>
de m
cy tot
coll ected</w>
calcul ated</w>
be low</w>
an e-
album in</w>
a y.</w>
D ec
-1 0</w>
th re
subj ective</w>
propor tion</w>
o d.</w>
mg .</w>
mer ic
fl uc
dehydro gen
consc i
con current</w>
analgesi c
P V
P ),</w>
5-fluoro uracil</w>
yl ated</w>
w k</w>
sy mptom</w>
respecti vely</w>
neuro muscular</w>
is on
inv asive</w>
er v
coll ag
cit alop
ce phal
angio graphy</w>
K- 80
10 00</w>
un changed</w>
smo k
per me
ill in</w>
glomerul oneph
f oun
f iltration</w>
emb olic</w>
deple tion</w>
ar y,</w>
Ph armac
I D
A meric
A E
( W
s ot
re search</w>
prophyl actic</w>
mg/kg .</w>
ide -induced</w>
excit atory</w>
ex tra
erg y</w>
enc ing</w>
de si
cal cit
ca ud
ca ro
3 0%</w>
volunte ers</w>
ti mo
superi or</w>
stopp ed</w>
s ou
ol ig
o ,</w>
ha z
control s,</w>
ca ution</w>
block ers</w>
N- methyl-
M ul
Ei ght</w>
Ca 2
8- year-old</w>
4 7</w>
vari ables</w>
tuber culo
rang ed</w>
poten cy</w>
popul ation.</w>
hum ans</w>
hepar in-induced</w>
gen ital</w>
en s</w>
az athiop
T ,</w>
Com pared</w>
AD R
vomit ing,</w>
tic ,</w>
testo sterone</w>
ter ms</w>
ter but
spectr um</w>
ph leb
patter ns</w>
infec tion.</w>
di c</w>
cy te</w>
cur ve</w>
beta- adrenergic</w>
arg et
agg reg
S uc
R is
NS AID
Im mun
B ,</w>
met oclop
fentan yl
expos ure.</w>
abs or
P H
NO S</w>
yg d
spre ad</w>
remif entan
recept ors,</w>
microscop ic</w>
mic rom
maz en
leuk o
i ron</w>
g/ m
effect ,</w>
col chic
characteris tic</w>
analy ses</w>
am ygd
aff inity</w>
MA IN</w>
A V
ther mal</w>
s low</w>
respon sive</w>
mid d
lat ter</w>
kg ,</w>
intoxic ation</w>
hyperalgesi a.</w>
h ero
gen otyp
ful l</w>
event s.</w>
dynam ics</w>
[3 H]
4 3</w>
1 5-
weak ness</w>
tre n
th ym
sur ve
phosph or
insi pid
in h
ho od</w>
fe wer</w>
discontinu ed.</w>
der s</w>
dec line</w>
ant .</w>
al ing</w>
ad y</w>
acqu ired</w>
S O
2- year-old</w>
-1 )</w>
vas ospas
tri meth
se pt
s am
present ation</w>
pharmacokine tic</w>
ouab ain
myoclon us</w>
lim it
diff use</w>
d in
aud itory</w>
ant s,</w>
a e</w>
T en</w>
S T</w>
An im
y sm
ves sel
veloc ity</w>
s on</w>
m Glu
iz ation.</w>
ci prof
amin o</w>
U nit
T .</w>
N or
F o
D R
(1 0
tr ypt
techniqu e</w>
sli ght</w>
presc ri
post erior</w>
kin in</w>
iti s,</w>
is he
inf iltr
f le
dose- response</w>
disturb ances</w>
ant ,</w>
acid ,</w>
a sis.</w>
TION S:</w>
P L
Increas ed</w>
zidov udine</w>
uc ul
to pro
sol u
se em</w>
rever sib
resp ect</w>
re d,</w>
pro posed</w>
model ,</w>
me topro
mac roph
f ever</w>
enc ies</w>
deteri oration</w>
confir m</w>
bene f
b ound</w>
arach no
Li ver</w>
F ,</w>
C oca
3 /
3 ),</w>
2 5%</w>
ve d,</w>
th ,</w>
test ,</w>
t arget
se x</w>
se d,</w>
ques tion
prost ate</w>
po d
mg/m (2)</w>
mE q/
i on
gene sis</w>
func tions</w>
el ective</w>
demonst rates</w>
death s</w>
coca ine,</w>
cell s,</w>
asth en
al kal
ad renal</w>
acet aminophen
P P
IC H</w>
C G
5 5
0. 6</w>
( r</w>
un d</w>
th ick
qu ality</w>
micrograms/ kg</w>
lact ate</w>
h imb
dose- limiting</w>
clo se</w>
bl ind
avoid ance</w>
an tr
am ine
adv ant
administ ere
METHOD :</w>
7. 5</w>
uter ine</w>
ul tra
tro n</w>
ro se</w>
microscop y</w>
lup us</w>
ist ry</w>
hyper kal
ex clu
diar rhe
defici ent</w>
N either</w>
Ex perim
Ad riam
4 1</w>
0.0 5</w>
( e
( 4.
w ise</w>
w ild
t able
su mm
stimul i</w>
ser v
sequ el
rang ing</w>
par athyro
p. o
nephro pathy.</w>
lin es</w>
lat er.</w>
l ind
inte gr
i es,</w>
comp eti
ch ain</w>
ST UD
D F
D 1</w>
4 5
(0. 5</w>
the l
re present</w>
po i
pl ays</w>
leng th</w>
k -
he ter
grad ually</w>
epi lept
compon ent</w>
clo sely</w>
an dro
an -
acet ate</w>
P ain</w>
10 ,</w>
un known.</w>
s qu
progester one</w>
proble m</w>
patient s)</w>
oph thal
oc clu
neuro toxic</w>
iti es,</w>
intraperitone ally</w>
exc re
dose- dependently</w>
dis played</w>
cyclospor ine</w>
coun ts</w>
chron ically</w>
cerebell ar</w>
S ),</w>
HB e
B .</w>
- mediated</w>
z ole</w>
trans amin
tom ography</w>
to ok</w>
tiv ari
supplement ation</w>
short -term</w>
reg urg
phenyleph rine</w>
inhib its</w>
ine ff
expl ain</w>
er mal</w>
doc etax
cysti tis.</w>
concentr ations.</w>
ch ing</w>
behavi ors</w>
bac lofen</w>
angiotens in-
ame ter</w>
agent s,</w>
Unit ed</w>
Stud y</w>
P hy
My ocardial</w>
H R
DO X
Ch ang
A g</w>
ures ,</w>
suscepti ble</w>
side -induced</w>
se tron</w>
schizophren ia</w>
prob ability</w>
pe g
particip ants</w>
p anc
ol ip
immuno hist
f ati
end omet
em phasi
dipyridam ol
deli very</w>
cy ste
al azine</w>
U )</w>
Signific ant</w>
L- N
4 9</w>
ycl ic</w>
signific ance</w>
prolifer ation</w>
ox amine</w>
n ess.</w>
medic ation.</w>
ing ly</w>
evid ent</w>
aminotrans ferase</w>
ag grav
M M
M K-80
1 5.
(1 5</w>
val ent</w>
u me
star t</w>
se -
s w
occur red.</w>
o ural</w>
implic ations</w>
hyp ox
exc ess</w>
ec ain
condition ed</w>
INT ER
I T</w>
F rom</w>
B ased</w>
w ays</w>
tra um
tr am
sig n</w>
recogn ition</w>
quin idine</w>
proced ure</w>
partic ular</w>
ob lastic</w>
interfer on</w>
immunosup pressive</w>
enc y,</w>
do g</w>
depres sion.</w>
d s.</w>
cros s
anxi et
antin ociceptive</w>
aff ecting</w>
Sub j
P ar
ME NT
Hear t</w>
F lu
1- year-old</w>
st aining</w>
re uptake</w>
oxic ity</w>
opio id
ischem ia.</w>
is m,</w>
immuno deficiency</w>
depart ment</w>
captop ril</w>
bu lo
bec ome</w>
amplit ude</w>
amide ,</w>
ag ne
QT c</w>
ven ess</w>
vasopress in</w>
v ar
set ting</w>
sec re
pro min
par alysis</w>
investig ated.</w>
ing u
hyperprolact inemia</w>
hydro chlorothiaz
furosem ide</w>
el ect
cor responding</w>
conver sion</w>
can not</w>
barri er</w>
am id
al anine</w>
T ran
G en
F in
C P</w>
(1 -
unc lear
ul cer
th .</w>
sam ple</w>
ocy cl
ochrom e</w>
n asal</w>
is om
inf ant</w>
fenflur amine</w>
fe ren
el uc
bo y</w>
antagon ism</w>
all ergic</w>
al low
ag ain</w>
ER I
DO X</w>
Compar ison</w>
6 0
2. 0</w>
wild -type</w>
we l
tri ax
time .</w>
su mat
small er</w>
rel b
re placement</w>
phenomen on</w>
mod ulation</w>
it .</w>
intrac ellular</w>
ino relb
inf iltration</w>
id en
i .</w>
fl ut
evalu ated.</w>
determ ined.</w>
def ect
cholinester ase</w>
beg an</w>
bac k</w>
b yp
STUD Y</w>
E arly</w>
sumat ript
smo oth</w>
s.c .)</w>
ru ption</w>
p .</w>
orth ostatic</w>
mac ro
lim b</w>
l umb
in ser
ide s</w>
i ble</w>
fe ver,</w>
eph ed
enh ance</w>
dis ul
diet ary</w>
coun ter
cle arly</w>
carbam azep
ar ab
acid .</w>
L E
H ere
H ,</w>
9- year-old</w>
3 5
1 4.
yl ine</w>
vit ro
subj ected</w>
se p
sal ic
per man
paracetam ol</w>
ograph y.</w>
no w</w>
monke ys</w>
model s.</w>
le sion
hal f-
bic ucul
allodyn ia</w>
al one,</w>
stimul ating</w>
show ing</w>
sevo flurane</w>
respectively )</w>
qu e</w>
pressu res</w>
picrotox in</w>
par a
ous ly.</w>
hist ologic</w>
fact ors.</w>
appro ach</w>
aim ed</w>
T d
S D</w>
Dop pl
1 3.
us t</w>
struct ure</w>
sti l
som e
simil ar
seroton ergic</w>
prot ected</w>
mum ol/
ment s.</w>
m am
haem orrh
h ere</w>
fasc icul
ex pected</w>
embr yo
em plo
d ly</w>
alter ation</w>
a emic</w>
F e
D- penicillamine</w>
8 ).</w>
(N S
system s</w>
s low
ret inal</w>
prot ect</w>
proced ures</w>
present ed.</w>
perf used</w>
off sp
neuro trans
mo l</w>
mal form
infarc tion,</w>
ine ur
experim ent</w>
effec tively</w>
detect able</w>
bir th</w>
auto immune</w>
ar yn
S A
D 3</w>
( IC
under taken</w>
suff ering</w>
rec tal</w>
ratio s</w>
r in</w>
ph ot
oxid ase</w>
out patient</w>
ol ine</w>
lamiv ud
headache ,</w>
d d
d ;</w>
cannab in
attribut able</w>
abil ity.</w>
reach ed</w>
r e</w>
ocicep tion</w>
nicot ine-induced</w>
k ain
hospit alized</w>
gir l</w>
distinc t</w>
d an
consci ous
caro tid</w>
bu s</w>
arter ies</w>
I O
H er</w>
G r
50 ,</w>
ver sion</w>
ter al</w>
pl an
ovari an</w>
op yr
measure ment</w>
inter ven
infec tions</w>
exam ined.</w>
er -
contracep tiv
aut onomic</w>
am bul
Sever al</w>
H U
6 ).</w>
withdraw n</w>
us al</w>
tu be</w>
pro ved</w>
prev ents</w>
predic tive</w>
os ing</w>
ome tr
o vir</w>
manner .</w>
le ar</w>
is su
ig n</w>
ic ity</w>
electro physiological</w>
cycl ic</w>
capac ity</w>
b est</w>
atic ally</w>
ardi ve</w>
arachno id</w>
afferen t</w>
S ome</w>
IS O
E M
D X
( 4</w>
us ers.</w>
tic -induced</w>
retino ic</w>
phen otyp
manifest ed</w>
last ed</w>
in otropic</w>
eth in
ep e
en tial</w>
cardiom y
ax onal</w>
anti gen
R A
PR L</w>
Hy poten
H ospit
wh ole</w>
vancom ycin</w>
th or
stil be
sle ep
over dose.</w>
ma k
m s,</w>
insul in</w>
h )</w>
es oph
epileptic us.</w>
em erg
duc t</w>
cyt ochrome</w>
cross over</w>
const ant</w>
competi tive</w>
apomorph ine-induced</w>
anti tumor</w>
N )</w>
Chang es</w>
C 57
-1 0
-1 ,
+ )</w>
(2 )
ur ation</w>
tic lop
ta ining</w>
t one</w>
stilbe stro
st s</w>
si rolimus</w>
pharmacokine tics</w>
iso flur
hallucin ations</w>
group s:</w>
gem cit
g ain</w>
es :</w>
diltiaz em</w>
cas e-
anticoag ulation</w>
Ne ph
N it
C ase</w>
B M
0.05 ),</w>
( median</w>
yo himb
ti tr
ten ded</w>
t )</w>
substanti al</w>
sub cut
re presents</w>
prospecti vely</w>
pro x
op ril</w>
neuro toxicity.</w>
myocardi um</w>
morb idity</w>
mal ar
ju g
intra -
immunore activity</w>
if ied</w>
i. c.v
he at</w>
fix ed</w>
eti ology</w>
ent s.</w>
control led,</w>
CH F</w>
B P
us cit
thyro idis
thyro id</w>
tachycardia ,</w>
syn erg
sing le-
si x
o pa
nicot inic</w>
i on</w>
es ;</w>
den af
compar ing</w>
cas e,</w>
bradycardia .</w>
at es.</w>
anti cholinergic</w>
anthracycl ine</w>
ant o
ant ine
V PA
ST -
S A</w>
R ating</w>
I P
( Group</w>
vol ume
sym path
s or
rout ine</w>
po ison
os yn
optim al</w>
nephro genic</w>
medi a</w>
mark ers</w>
ine d,</w>
glob al</w>
ecti vely</w>
drin king</w>
def in
chemo therapeutic</w>
biopsi es</w>
attac ks</w>
Me dian</w>
H is</w>
C l</w>
valv ular</w>
rec tom
orph ine</w>
no de</w>
n ational</w>
mo od</w>
los s.</w>
docum ent
consequ ences</w>
cocaine- dependent</w>
cho ice</w>
cerebro spinal</w>
beat s/
ane -induced</w>
am ant
M -
A u
seiz ure
recor ds</w>
pharmac ologic</w>
perme ability</w>
o ve
ne ver</w>
m os
le thal
foun d.</w>
flu mazen
f ur
ex ce
dos ages</w>
defic it</w>
d ri
convul sions.</w>
control ,</w>
consequ ence</w>
c re
and s</w>
S event
O r
I so
Hi gh
AM E</w>
(2 00</w>
wel ve</w>
ventric le</w>
um erous</w>
ri a</w>
recor ded.</w>
pro fen
p ast</w>
ox ane</w>
metho ds</w>
medetom idine</w>
ir rit
in- associated</w>
hyper plasia</w>
headac h
glomerul i</w>
cur onium</w>
cr yst
compl ain
av oid</w>
U C
J ap
Gr ade</w>
Doppl er</w>
C57 B
4 ),</w>
stra in</w>
st em</w>
reac tion.</w>
pre lim
pap illary</w>
pa w</w>
p el
om otor</w>
morph ological</w>
m io
ine :</w>
in )</w>
ex ter
ede ma,</w>
dil ated</w>
chemo therap
amygd al
am il
am but
W e
U r
Phy si
For ty-
D .</w>
0.00 1),</w>
uti li
uni que</w>
spec ies</w>
s keletal</w>
s atis
resid ual</w>
promin ent</w>
predomin antly</w>
pivaca ine</w>
p in
ox yl
o vascular</w>
new ly</w>
n atal</w>
microm ol/
me perid
isoniaz id</w>
ing ly,</w>
hemo dialysis</w>
f ast
condi tions.</w>
behavi oural</w>
am it
al in</w>
T M
M R</w>
Long -term</w>
L o
H )
5 8</w>
5 7</w>
10 (-
( 4-
ure th
ure mic</w>
supra ventricular</w>
rema in</w>
performe d.</w>
o sis,</w>
nex t</w>
mening itis</w>
load ing</w>
l ess
ithrom ycin</w>
inf requ
fl ecain
ent ered</w>
dail y,</w>
caref ul</w>
ab le,</w>
L ith
Di fferen
D B
Com b
5 3</w>
thrombo embolic</w>
system ,</w>
sol ute</w>
prednis one</w>
phy sos
pathophysi ology</w>
olog y.</w>
me lat
le uc
k noc
intra vascular</w>
intr ad
haloperid ol.</w>
g/ d
dig it
at en
am ,</w>
M et
J an
I f</w>
Fin ally,</w>
E ach</w>
E T
2 ;</w>
to ward</w>
te mpt
sil denaf
se e
scre ening</w>
res uscit
ras h</w>
prelim inary</w>
om al
medi al</w>
lowe red</w>
lo ad</w>
l ation</w>
ir reversible</w>
inf or
hero in</w>
ed -
di p
cirrho sis</w>
chang es,</w>
can ine</w>
all -
ac ro
ac count</w>
SI AD
IV )</w>
GF -
. g
(H B
( K
y s.</w>
y ric</w>
x ameth
ver sity</w>
tu bulo
sub arachnoid</w>
stopp ing</w>
st om
sensi tiv
prospecti ve,</w>
proble ms</w>
phosph olip
mg/kg/ day</w>
me ll
man ag
intramus cular</w>
ine- associated</w>
imi pramine</w>
ill ust
femal es</w>
erythro poi
ede ma.</w>
dys function,</w>
develop mental</w>
amit ript
amide -induced</w>
V al
PA )</w>
MA T
Af ric
0. 8</w>
( 5.
valu es.</w>
temperat ure</w>
ri fic
pac ing</w>
ox antr
minut es.</w>
microgram /
mal es</w>
l ing
if ost
i el
end oc
duc t
decreas ing</w>
con sti
c lop
attenu ate</w>
ap ine</w>
antibio tic</w>
an emia,</w>
abnormal ities.</w>
S p
GABA ergic</w>
G ,</w>
( a</w>
( 40</w>
wom en.</w>
ventil ation</w>
vasocon stric
under g
ser ial</w>
sac rific
rhabdomy olysis</w>
res s</w>
requir e</w>
r amide</w>
op ulmonary</w>
olog ic
lithi um-induced</w>
ligi ble</w>
kind led</w>
id azol
h ar
f lo
eryth emat
dyston ia</w>
de v
ac ts</w>
ab use.</w>
O ral</w>
Neph ro
Grou ps</w>
youn ger</w>
vari able</w>
tivari ate</w>
schedul ed</w>
ra ised</w>
pl ast
per ox
mg/m 2/
mell it
low ering</w>
li pos
inc re
in s.</w>
in appropriate</w>
f as
docetax el</w>
diseas es</w>
discontinu ing</w>
dis mut
amide .</w>
alk alo
ac etic</w>
R et
Hep ar
G S
D N
7 ).</w>
50 -
4 6</w>
4 0%</w>
z om
transpor t</w>
ti car
threshol ds</w>
sol id</w>
soci al</w>
responsi veness</w>
respon d</w>
recept or-
pro mpt
plac e</w>
p up
on es</w>
olog y,</w>
midd le</w>
lim it</w>
inorelb ine</w>
hypothesi zed</w>
haem at
fo ot</w>
f inal</w>
discharg e</w>
dec l
cortis ol</w>
cle .</w>
bic arb
angio graph
acid osis</w>
U T
N P
L A</w>
AID S</w>
A D</w>
7 6</w>
ul c
tric yclic</w>
thor ac
shor tly</w>
s ha
prog no
produc t</w>
otom y</w>
opi ate</w>
hypercal cemia</w>
g ol
enc oun
cortico steroid</w>
continu ously</w>
blood- brain</w>
ather os
ap ar
analy sis,</w>
anaesthe tized</w>
ac u
Re ver
O -
MR I</w>
L- DO
Jan u
C ap
AM P</w>
6 7</w>
) :</w>
war r
un ilateral</w>
ty ros
suc c
sign aling</w>
re cur
press ing</w>
placebo ,</w>
it s.</w>
hyp oc
graf t</w>
follow-up .</w>
em ent.</w>
doxorubic in.</w>
creat in
cimeti dine</w>
ch i
VE N
T A
L ab
AT P</w>
0. 7</w>
0 /
(-1 )</w>
y ri
us h
ul ate</w>
tro p
timo lol</w>
th em
stimul ation.</w>
sp ac
se min
s clero
prov o
neut roph
neuropath y,</w>
mo tion</w>
medi um</w>
li gn
injur y,</w>
in hal
hyperalgesi c</w>
hemorrh age.</w>
fel l</w>
fam ily</w>
discus sed</w>
dep olar
def ect</w>
cir c
ation :</w>
R F
D ,</w>
8 7</w>
00 -
(4 )</w>
y iel
x y
st er</w>
simult aneously</w>
se l</w>
relap se</w>
re infor
praz osin</w>
plat in
ot al</w>
my asthen
mat ter</w>
ine /
id az
ia :</w>
i )</w>
hype remia</w>
ey e</w>
chlorpromaz ine</w>
S SR
S R</w>
P os
M ,</w>
INTER VEN
I L-
G .</w>
vul ner
un its</w>
tram ad
thiop ent
tetra hydro
syn thetic</w>
sp e
rest ored</w>
resp ective</w>
regimen .</w>
on azole</w>
numb ers</w>
ma x
investig ations</w>
in os
hel p</w>
establ ish</w>
elev ations</w>
diclofen ac</w>
dehydrogen ase</w>
cyto plasmic</w>
cir cum
cathe ter</w>
ati vel
antidepress ants</w>
an n
Rec ent</w>
Q RS</w>
MAT ERI
D P
CA 1</w>
C E
An g
5 6</w>
1 ;</w>
(0. 1</w>
ysm al</w>
un common</w>
stra ins</w>
shor ter</w>
rig id
rele as
refer red</w>
pre term</w>
potenti ation</w>
perman ent</w>
ocy tic</w>
ng/ ml
min oxidi
main tain</w>
inter vention</w>
inf erior</w>
increas ed.</w>
fibrill ation.</w>
elect rom
det ect</w>
cyste ine</w>
cer v
b ran
atroph y</w>
as h
arth ritis.</w>
ag it
a udi
P a
N-methyl- D-
C lo
C entr
AS A</w>
3. 0</w>
1 8.
theli um</w>
tempor ary</w>
t ardive</w>
subj ect</w>
statis tical</w>
simult aneous</w>
seve rely</w>
retro specti
pum p</w>
pa ir
omet ric</w>
mother s</w>
in somn
g on
fe ed
estim ate</w>
eff ici
d ap
correc ted</w>
consist ing</w>
ch ore
Subj ects</w>
N ine</w>
Janu ary</w>
II ,</w>
H D</w>
Anim als</w>
(O H)
vi sion</w>
un chang
ter s</w>
syn the
re mark
p H</w>
lo dipine</w>
lab et
ing est
ine ;</w>
h il
gluc o
epirub icin</w>
electrocardio gram</w>
depres sion,</w>
del ay</w>
byp ass</w>
brie f</w>
ar rest
U se</w>
S yn
N E</w>
MK-80 1</w>
M ed
L-N AME</w>
In trac
H alo
H R</w>
D el
C y
5 ),</w>
. ),</w>
( EC
yc in.</w>
ventr al</w>
v ec
un known</w>
sion -
self- administration</w>
seem ed</w>
remifentan il</w>
psycho sis</w>
pro ven</w>
pl asi
pas sive</w>
nephro sis.</w>
neg ati
methyl prednisolone</w>
low est</w>
los artan</w>
locom o
ll ing</w>
line ar</w>
indometh ac
frac tional</w>
fr ag
etom idate</w>
electroly te</w>
der ,</w>
cocaine- associated</w>
c ranial</w>
c ra
as yst
an e.</w>
] -
S ide</w>
M an
6 6</w>
5 9
. ).</w>
+/ -1
unclear .</w>
tissu es</w>
thromb in</w>
man ner</w>
lith iasis</w>
ic k</w>
hour s,</w>
fact ors,</w>
equi valent</w>
endomet rial</w>
emplo y
echocardi ographic</w>
cyclophosphamide -induced</w>
cortex ,</w>
comple tion</w>
cef triax
b )</w>
angiotensin- converting</w>
analo gue</w>
Re g
N- acetyl
F 1</w>
6 1</w>
3. 5</w>
(P T
(A D
tra ining</w>
thrombo embolism</w>
terbut aline</w>
suffici ent</w>
ser tr
se s,</w>
ri min
rad ical</w>
pro gram
praz ol
path ology</w>
on se
ol i
myoclon ic</w>
minim um</w>
level ,</w>
gli al</w>
fe a
ex tre
er 's</w>
compon ents</w>
ation )</w>
analo g</w>
al ways</w>
air way</w>
age al</w>
Sub sequ
M in
L V
I ts</w>
G T
G E
CB F</w>
1 6.
vi ron
val ve</w>
vacu ol
syncop e</w>
ser ved</w>
s well
rou gh</w>
ri tis,</w>
ret in
phleb itis</w>
pathw ays</w>
part um</w>
myo pathy.</w>
lumb ar</w>
ibu profen</w>
hydro chlor
gu ine
glomeruloneph ritis</w>
f un
f re
dog s,</w>
depend ence.</w>
de le
dat ab
chrom at
carcin oma.</w>
canc er,</w>
azathiop rine</w>
appro ach
alle vi
ac yclo
Th rom
M ic
Ei gh
( +/-
te trac
succinyl choline</w>
su xameth
sal ine,</w>
profi les</w>
op sy</w>
neo plastic</w>
mortal ity.</w>
mes na</w>
meas uring</w>
man nit
knoc k
is op
hospit al.</w>
ep tic</w>
ectom ized</w>
da un
d :</w>
cyt osine</w>
contrac tion</w>
com mun
at tempt
arrhyth mia.</w>
ap ri
amino glyco
abil ity,</w>
With in</w>
U -
SM -
L ).</w>
Hi gh</w>
He al
FK50 6</w>
Americ an</w>
(E D
vie w
sugg estive</w>
smo king</w>
pr ur
pilo t</w>
p ol
o il</w>
norep inephr
metopro lol</w>
lind ane</w>
iz ation,</w>
first- line</w>
dist ingu
diethyl stilbestro
dex tro
cerebro vascular</w>
ce ,</w>
cap illary</w>
behavi our</w>
an e,</w>
amin ophylline</w>
al located</w>
St udi
HIV -
C arb
(2. 5</w>
wide spread</w>
ut ure</w>
spec imen
sou ght</w>
pi per
panc re
obut yric</w>
n im
me gal
maz e</w>
inh aled</w>
in tak
h ap
fav or
f usion</w>
eth ambut
est er</w>
catech olamine</w>
attenu ation</w>
alg ia</w>
adenocarcin oma</w>
T ri
S ).</w>
He pati
B et
7 3</w>
7 .</w>
0. 0</w>
(2 5</w>
(+ )</w>
we l</w>
ut ing</w>
thrombo sis.</w>
ter ol</w>
subject s,</w>
so ur
shor t-
re activity</w>
prepar ations</w>
po or
physici ans</w>
peritone al</w>
mg/ d</w>
lab el</w>
hear t.</w>
expl ained</w>
correl ate</w>
con junc
circul ating</w>
bradycardia ,</w>
be ats</w>
ati tis</w>
Seiz ures</w>
P B</w>
L VE
viv o.</w>
sul piri
sc an</w>
retur n</w>
response s.</w>
protein uria.</w>
prot ects</w>
propyl thio
proces ses</w>
pres er
om a,</w>
nucle ar</w>
neuron s.</w>
necro sis.</w>
m L/
le sions.</w>
dys rhyth
dizzin ess</w>
di men
deteri or
dail y.</w>
channel s</w>
block .</w>
b is
atri ure
as p
ar ch
aff ective</w>
Pro po
Per i
P rop
Hypoten sion</w>
D ex
6 4</w>
yl )
vag inal</w>
u los
tas k</w>
sus p
relie f</w>
procain amide</w>
post natal</w>
phasi c</w>
ou s,</w>
opo i
nat ure</w>
men opa
mechanis ms.</w>
m im
leuko encephalopathy</w>
le ven</w>
f if
en viron
ect ed.</w>
derivati ves</w>
compl i
compar ative</w>
c m
aneur ys
anaesthe sia.</w>
an ol</w>
acc umb
absor ption</w>
MEASURE MENT
Cs A</w>
C M</w>
ur on
struct ures</w>
re sem
prom pt</w>
post ural</w>
obstruc tive</w>
mucos al</w>
min ocycl
kine tic</w>
in- related</w>
ifost ine</w>
iden tical</w>
hemat oma</w>
glucocortico id</w>
fi ram</w>
enh ances</w>
ecoxi b</w>
e ;</w>
der mal</w>
contracep tive</w>
concentr ation.</w>
con genital</w>
case- control</w>
at or
asi c</w>
amoun ts</w>
am b
Studi es</w>
M .</w>
7 8
4 0-
yl ation</w>
surger y,</w>
schizophren ic</w>
repor ting</w>
reg ard</w>
pos ses
poor ly</w>
paralle l</w>
oc tre
nitro -
neurotrans mit
me ly</w>
indin avir</w>
event s,</w>
ev ol
dou ble</w>
continu ation</w>
condi tions,</w>
chol ec
at tem
anti diuretic</w>
ant ed</w>
an con
al fentanil</w>
Dru g
B r
20 ,</w>
/ -
- to-
(- )-
under sto
tion ally,</w>
so ,</w>
ra ph
qu eti
predic t</w>
pap er</w>
p all
n atriure
multicent er</w>
metoclop ramide</w>
label ed</w>
intrac erebro
h er
gest ation</w>
erythemat os
em is
che mic
cat at
arter io
al do
al de
a uc
SN P</w>
PA N
Over all,</w>
N P</w>
BACKGROUN D</w>
A P</w>
8 5</w>
0. 3
vec ur
vari ed</w>
scop olamine</w>
re ference</w>
qu al
predict ors</w>
ox al
otoxic ity,</w>
om y
ocy to
occa sion
mg/ day)</w>
lithi um-
k illed</w>
iz ed.</w>
identifi ed.</w>
gentam ic
di phen
cyt es</w>
cont ribution</w>
colchic ine</w>
col on
citalop ram</w>
block ade
bilirub in</w>
ben ign</w>
arab ino
an at
Tran si
P B
G i
Dox orubicin</w>
B i
4 ,
( r
vag al</w>
v inorelbine</w>
the ophyll
significant .</w>
restric ted</w>
requi re
reac tions.</w>
of f</w>
modi fy</w>
it sel
in dependently</w>
id ine,</w>
gy rus</w>
gly ce
fol ic</w>
extre mely</w>
di ameter</w>
de mo
condi tion.</w>
comp uted</w>
clin icians</w>
calcit ri
aw a
attenu ates</w>
at el
amin obutyric</w>
alde hy
Twent y</w>
SH R</w>
PATIENT S:</w>
P sych
O 2</w>
METHOD S</w>
L ),</w>
F ancon
C F
10 )</w>
( from</w>
z ed.</w>
ur ticar
subst ances</w>
st ly</w>
s ph
res ,</w>
qu inine</w>
methyl phen
lay er</w>
hydrox y-
granulo mat
di lat
cortico steroid
comp ens
bo wel</w>
anti retro
am is
aggres sive</w>
ac cur
] .</w>
C at
C R</w>
A V</w>
5- hydroxy
0. 9</w>
( c
u sions</w>
tre x
sal ine.</w>
regul ated</w>
precipit ated</w>
prece ded</w>
perid ol</w>
paren teral</w>
myocardi tis</w>
mix ture</w>
melat onin</w>
lis in
li qu
isop ren
io hex
ific ation</w>
finding s,</w>
fas hi
en ergy</w>
embryo s</w>
e ous</w>
e ach
discus s</w>
disc rimin
collag en</w>
ciprof loxacin</w>
am .</w>
acid s</w>
O H-
C ol
7 7</w>
1. 2</w>
(p <
vis c
t ase</w>
sot alol</w>
sign al</w>
relax ation</w>
re produc
re ady</w>
potenti als</w>
ogen ous</w>
nerv es</w>
mos sy</w>
min al</w>
mGlu R
long- lasting</w>
l ide</w>
induc ible</w>
increas ingly</w>
implant ed</w>
il -induced</w>
g ad
four th</w>
excl uded</w>
del ta</w>
coag ulation</w>
cardi otoxic</w>
car nit
bio logical</w>
arrhythmi as,</w>
apne a</w>
an omal
al is</w>
Re por
Pro long
Pos sible</w>
N ar
ME TH</w>
Contro l</w>
C57B L/
6 3</w>
0.000 1).</w>
tyros ine</w>
tri als.</w>
the refore,</w>
strate gi
spas m</w>
rep olar
r al
pyri dox
neuro genic</w>
n es
mit oxantr
lipos omal</w>
it rate</w>
gre l</w>
fr act
form ul
en -
electrom yo
de sign
d s,</w>
ar ing</w>
ang ial</w>
acid -induced</w>
ac ross</w>
U ni
S ur
R .</w>
PA R
N on
E p
7 0
6 2</w>
5 9</w>
3 0,</w>
2 5,</w>
u sion.</w>
tum ors.</w>
test s.</w>
te zom
ta il</w>
substanti a</w>
stit uted</w>
sit u
sequ ence</w>
regurg itation</w>
rabb its</w>
ot otoxicity</w>
organ ic</w>
nephro toxic</w>
na prox
ishe d.</w>
inter pre
influ enced</w>
if y</w>
histopath ological</w>
exacerb ation</w>
eme tic</w>
dis semin
dem enti
de grad
cytot oxic</w>
contribut ing</w>
clo mi
baro reflex</w>
acc id
ab solute</w>
Z )</w>
Transi ent</w>
Ne w</w>
MATERI AL
M S</w>
E valu
3 4
tri al,</w>
t on</w>
t ary</w>
stop pe
sequ ential</w>
s at
ratio ,</w>
rad ic
promis ing</w>
pr inc
os ar
n umerous</w>
lesion ed</w>
hyp om
he av
he al</w>
glomer ulos
finding s.</w>
episo de
elim ination</w>
difficul t</w>
di hydroxy
contribut es</w>
combin ations</w>
but am
basel ine,</w>
ation ;</w>
ap l
ac cumul
Thir ty</w>
T welve</w>
P/ d
I s</w>
Ch in
CO 2</w>
0.0 1),</w>
(i. e.,</w>
y -induced</w>
ves sel</w>
termin ation</w>
tac rolim
streptozotoc in</w>
specific ally</w>
sc i
proper ties.</w>
produc ts</w>
phenyleph r
patient s'</w>
par as
oxygen ase</w>
out put
nit r
m atic</w>
lidoca ine.</w>
knock out</w>
i.p. ),</w>
h and
f in
en ox
en ed</w>
disorder s,</w>
determin ation</w>
d P/d
at rop
amin o-
albu min
ad junc
N ine
Here ,</w>
CO M
C yclo
C al
AIM S:</w>
6 9</w>
(P AN
trans ferase</w>
thorac ic</w>
ro d
retic ul
requi res</w>
outcom e.</w>
odi um</w>
ochem istry</w>
new born</w>
nec k</w>
menopa usal</w>
medull a</w>
inhib i
inc or
g y</w>
flow .</w>
equ ally</w>
ephed rine</w>
deriv ative</w>
consist ently</w>
compl ained</w>
bacter ial</w>
at rac
ast er
asses sed.</w>
P F
M o
In iti
C s</w>
C D</w>
(M T
war ds</w>
vast at
ton ic-
tin nit
st one</w>
sel ectively</w>
sel ec
s or</w>
pentobarbit al</w>
path ologic</w>
ond an
ne t</w>
nat ural</w>
n mol
me l
kine sia</w>
iso prost
inhibit or
ex t
encephalo pathy.</w>
electro physiologic</w>
cult ured</w>
con cent
cerv ical</w>
achie ve</w>
V -
Suc h</w>
N-methyl-D- aspartate</w>
Clin icians</w>
AR F</w>
(C B
y ).</w>
week ,</w>
ur in
ultra structural</w>
ten d
survi v
substanti ally</w>
subcut aneously</w>
su it
soci ation</w>
si ded</w>
record ings</w>
not ed.</w>
ne arly</w>
n mol/
ke y</w>
invol ve</w>
ine -</w>
i.p .,</w>
gluc uron
gemcit abine</w>
fo od</w>
fac t</w>
f ying</w>
f os
exce ed
disturb ance</w>
desc ending</w>
cortex .</w>
child hood</w>
ac idi
a :</w>
SC H</w>
O UT
E 2</w>
DE S</w>
D ep
Cardi ovascular</w>
Adriam ycin</w>
Addi tionally,</w>
5 %,</w>
00 ,</w>
(A )</w>
trans fer
tra z
termin al</w>
syndrom es</w>
survi val
second -
random ised</w>
question na
predic ted</w>
pre feren
per gol
ol s</w>
norm ally</w>
mg/m 2,</w>
ment s,</w>
local ized</w>
ling ual</w>
ine ural</w>
icac y</w>
hy bri
group )</w>
gl auc
emergen ce</w>
dismut ase</w>
der .</w>
dail y)</w>
d ate</w>
cortico steroids</w>
consi der</w>
be f
b .
attem pt</w>
antibio tics</w>
ambul atory</w>
al ready</w>
al az
administere d.</w>
ac hol</w>
Ris k</w>
Res pon
O R</w>
B -
9 6</w>
1. 3</w>
yohimb ine</w>
wh at</w>
ti es,</w>
stimul ant</w>
st a
s par
ren ess</w>
ren e</w>
progres sed</w>
po wer</w>
phosphat ase</w>
not .</w>
neuro protective</w>
neph ritis.</w>
mes angial</w>
medic ations.</w>
lor azepam</w>
inhibit ing</w>
ineff ective</w>
in ner</w>
hydrochlorothiaz ide</w>
hepati tis,</w>
fact ory</w>
exer t</w>
erec tile</w>
dissemin ated</w>
discharg ed</w>
den erv
decl ined</w>
cit rate</w>
caus al</w>
atrac ur
ate g
antipsycho tics</w>
anaesthe tic</w>
am yl
aff ects</w>
Simil ar</w>
IS O</w>
Fif ty-
Ca2 +</w>
B u
As ses
9 5</w>
9 0
6 8</w>
6 0%</w>
5-HT (1
3, 4-
1 5,</w>
( 7.
( 6.
y clin
vessel s</w>
vari ability</w>
ti ve,</w>
side s</w>
rat s:</w>
pre g
poly uria</w>
pati on</w>
path ic</w>
pac e
p <
om ime
measure d.</w>
intrad ermal</w>
inten se</w>
inhibit ors.</w>
ine 's</w>
he re
haloperid ol,</w>
gamma- aminobutyric</w>
foc i</w>
d u
contrib uted</w>
com for
bre ak
ameth ox
ad ver
T n
S af
E -
CYP 2
A ce
3 44</w>
(O R</w>
vasospas m</w>
vasocon striction</w>
trimeth op
transpor ter</w>
tonic- clonic</w>
ten sion</w>
t ment</w>
sumatript an</w>
sol ub
sec tions</w>
ro f
predisp osing</w>
poly mer
oz yg
ox y-
ni gr
mg/m (2
mal e
l af
laf ax
is ms</w>
il lo
haemo dynamic</w>
glyc ine</w>
glutam at
doxorubic in,</w>
dow n
character ize</w>
bre ath
amelior ated</w>
abnormal ity</w>
Ur inary</w>
Peri pheral</w>
P ac
N S</w>
Mic ro
M g
In hib
Centr al</w>
C lon
7 9</w>
4 /
(P R
(D E
we ak</w>
vesi cal</w>
vasodilat or</w>
var ying</w>
simil arly</w>
schizophren ia.</w>
s lic
review .</w>
prop an
pre existing</w>
pos ite</w>
other wise</w>
nephro toxicity.</w>
min -1</w>
mg/m 2.</w>
m ing</w>
in tran
in stitution</w>
in dex
ide -
hyponat remia</w>
flumazen il</w>
flow ,</w>
encoun tered</w>
ec it
disorder ,</w>
dam age,</w>
cy tic</w>
comp ris
co logy</w>
c im
analo gu
an ser
an ore
accept able</w>
V T
M on
M S
G F</w>
= 0.00
8 4</w>
6 ),</w>
5 1</w>
5 ,
1. 4</w>
(2 )-
us -
un related</w>
some times</w>
rec ru
protein uria,</w>
offsp ring</w>
obstruc tion</w>
no d
meth amphet
lymph oma</w>
lymph oblastic</w>
leuk emia.</w>
j ust</w>
insi c</w>
ill ness</w>
ho w</w>
gi ven
exhib it</w>
esoph ageal</w>
do m</w>
dex medetomidine</w>
con n
cholest asis.</w>
cas e.</w>
c ateg
anti convuls
an j
Nar anj
Ho dg
H IT</w>
Be havi
8 .</w>
2 %,</w>
(e .g
vascul itis.</w>
ther ,</w>
te tr
ste ad
ris k.</w>
retrospecti vely</w>
ran iti
r ul
pregnanc y.</w>
para dig
pace mak
ocyt es.</w>
occasion ally</w>
nucle i</w>
mechanis m.</w>
ly sos
liver .</w>
it y:</w>
insipid us</w>
inc ub
id ,</w>
i s.</w>
hippocamp us.</w>
h and</w>
g ro
et al</w>
dy st
di aph
cont in
cardi opulmonary</w>
bl ing</w>
benef its</w>
bar ic</w>
b und
an ese</w>
T ac
PA P</w>
P ri
Naranj o</w>
K et
IO P</w>
I /
Hg ,</w>
E D</w>
CB Z</w>
C e
8 0%</w>
6 %,</w>
x anth
tum our</w>
thiop ental</w>
tail -
sulf amethox
salic yl
respectively ;</w>
ra re.</w>
ot ec
osi tive</w>
os mo
o gen</w>
natriure tic</w>
mg/ day,</w>
l -induced</w>
intro duction</w>
incor por
id -
he mic
exter nal</w>
end oscop
en o
d end
calc ineur
benz o
az osin</w>
arteri os
appe ti
ana emia</w>
al er
V er
Syst emic</w>
R T
O c
NA ME
D D
B ra
An alysis</w>
7 4</w>
7 0%</w>
1 60</w>
vehic le
v in
ur rent</w>
trigg ered</w>
sildenaf il</w>
ren in-
recover y.</w>
re mis
prur it
pro st</w>
parameter s.</w>
on ol
myo si
mit ral</w>
me t</w>
mat ri
k s.</w>
im e</w>
gen es</w>
enter ic</w>
eluc idate</w>
deli ver
death ,</w>
de tail
cortico sterone</w>
con jug
chemo therapy,</w>
ana phyl
ain s</w>
M ore</w>
D L
AN CA
1 2,</w>
( 6</w>
vol t
un affected</w>
th o
suppor ts</w>
releas ing</w>
recomm end</w>
prolifer ative</w>
po w
pilocarp ine.</w>
par aly
p unc
osmol ality</w>
od rine</w>
myasthen ia</w>
man ia</w>
ir e</w>
ip )</w>
in :</w>
i ,</w>
hypercal ce
hydrox yl
hormon al</w>
glutamat ergic</w>
gest ational</w>
ge al</w>
et ing</w>
dizzin ess,</w>
cy st
cont ained</w>
compar is
clop ido
c old</w>
bal ance</w>
augment ed</w>
attac k</w>
am ycin</w>
acut ely</w>
T P
R an
R OD
Med ical</w>
HBe Ag</w>
Eff icacy</w>
9 0%</w>
9 ).</w>
8 2</w>
1. 6</w>
1 :
1 %,</w>
worsen ed</w>
w ash
ven tive</w>
tren d</w>
ti b
suit able</w>
stres s.</w>
st ep
so on</w>
scop ol
saf ely</w>
pi g
peroxid ase</w>
om yc
man ic</w>
li pide
i op
hyp no
hem olysis</w>
guine a</w>
fluox et
flecain ide</w>
fascicul ations</w>
ey es</w>
exer ci
es /
diseas es.</w>
de sign</w>
contrac tile</w>
conf oun
concentr ations,</w>
co de
caref ul
cannabin oid</w>
c och
az oc
ari pi
ar ly,</w>
am -
abstin ence</w>
ROD UC
P 450</w>
INT RODUC
HB s
CO X-
Am iodar
A L</w>
3 %,</w>
1 25</w>
(C H
year .</w>
y ch
su ic
resul ts.</w>
r af
pap aver
onol act
monit or</w>
min /
le t
label ing</w>
j oin
ing -
h n
fluo res
f uture</w>
expl an
ei gh
com pa
bil ater
bas ement</w>
antiretro viral</w>
alkal ine</w>
Saf ety</w>
S ymptom
N S)</w>
H em
F l
E leven</w>
CI :</w>
7 8</w>
5-F U
1. 8</w>
1 7.
0. 9%</w>
0. 5%</w>
um or</w>
tubulo interstitial</w>
swell ing</w>
suppor tive</w>
st ren
sim ple</w>
shorten ing</w>
sex ,</w>
s ca
repe ti
princ ip
prepar ation</w>
pre frontal</w>
patient s).</w>
parox etine</w>
opyr amide</w>
occlu sive</w>
nitr ite</w>
ml )</w>
mil li
log raf
liqu id</w>
levo dopa
in /
hyper ther
gener ated</w>
experi encing</w>
ex encephal
es ul
dyskine tic</w>
contro lling</w>
conscious ness</w>
carcin omas</w>
carb on</w>
beta- adrenoceptor</w>
antagonist s,</w>
anc es,</w>
amant adine</w>
am oxic
Th er
S G
R epe
MATERIAL S</w>
INTRODUC TION:</w>
Fif teen</w>
Dec emb
C erebral</w>
Asses s
AC TH</w>
3 ;</w>
2. 0
1 -1
(- /-
( 3-
u preg
tub ule</w>
tu mo
tri am
ti form</w>
sal butam
ra y</w>
psych ological</w>
practi ce</w>
p ine-induced</w>
om es</w>
mg/m 2)</w>
il ine</w>
id azole</w>
heav y</w>
gam ma</w>
fluo resc
exten ded</w>
erg ot
e asi
cy s
cent er</w>
az one</w>
adul ts.</w>
acet am</w>
Ther ap
Th us</w>
Rever sible</w>
O p
Heal th</w>
Drug -induced</w>
Ca (2
24- hour</w>
100 %</w>
trans -
thrombocytopen ia,</w>
striat um.</w>
sing le
secon ds</w>
sacrific ed</w>
ra re,</w>
ra -
propofol .</w>
pre pared</w>
pa fen
opio ids</w>
on going</w>
olan zap
oid s</w>
ogen icity</w>
ne ar</w>
mo bil
meperid ine</w>
medull ary</w>
lo o
large ly</w>
inf ants.</w>
id ine.</w>
gentam icin-induced</w>
fem oral</w>
exac t</w>
employ ed</w>
emis sion</w>
dis ruption</w>
der mat
cy pro
cur ves</w>
convul sion</w>
carb achol</w>
block s</w>
bicarb onate</w>
b er
at ally</w>
aryn geal</w>
anc ing</w>
al low</w>
al )</w>
adi ly</w>
ad d
Propo fol</w>
Prolong ed</w>
P K
L- NAME
AC h
( in</w>
use d,</w>
ta x
stat es</w>
sp ectro
si z
si c
see king</w>
scop ic</w>
reser ve</w>
point es.</w>
pent am
peg ylated</w>
parkinson ism</w>
knowledg e</w>
intrac or
in s,</w>
in o</w>
impair ment.</w>
i lo
i b</w>
hypo the
haz ard</w>
h ind</w>
exer ts</w>
ex cell
epinephr ine-induced</w>
e le
dram atically</w>
discontinu ed,</w>
diethylstilbestro l</w>
complic ation.</w>
circ ulation</w>
ce ph
catechol amines</w>
catal ase</w>
cardiomyo pathy,</w>
bu pren
bra ins</w>
bor tezom
au tis
at o
anticoagul ant</w>
al lograf
] )</w>
O b
Lab oratory</w>
F our
B /
7 %,</w>
5. 0</w>
year s;</w>
volunte ers.</w>
vascul ar
unchang ed.</w>
ul es</w>
tubul es</w>
tr act
tic .</w>
there by</w>
streptozotoc in-induced</w>
s.c .</w>
s ure</w>
reve al</w>
repor ted,</w>
re plic
rang e.</w>
post synaptic</w>
phosph o
ph er
pa w
p ly</w>
oph osph
oly sis.</w>
o plastic</w>
myelo ma</w>
mul tivariate</w>
los s,</w>
intr insic</w>
inter ac
fam il
ex plo
enti re</w>
enti n</w>
disul firam</w>
cor d
caus ative</w>
avoid ed</w>
anesthe sia,</w>
am ifostine</w>
alpha- methyl
ag ing</w>
ag es.</w>
SE .</w>
M I
M ),</w>
B as
Al so,</w>
A S</w>
1 A</w>
0 .</w>
( 8.
y me
under standing</w>
ud g
u ne
tumo ur
tramad ol</w>
tion )</w>
tig m
ti ve.</w>
seg ments</w>
ret ard
relap sed</w>
pati al</w>
p g/
ous ly,</w>
ogene sis.</w>
ob last
normal ,</w>
is ot
infu sion
i v</w>
form ation.</w>
fet uses</w>
ex ogenous</w>
entr y</w>
em a</w>
dur al</w>
drug -related</w>
carnit ine</w>
car r
canc er
bl un
belie ved</w>
belie ve</w>
b if
arg in
appro ved</w>
anto in</w>
ad ap
R NA
P N</w>
P -induced</w>
Mul ti
Immun o
Hospit al</w>
Evalu ation</w>
Decemb er</w>
Com ple
Chin ese</w>
C ).</w>
AM -
A A</w>
- cell</w>
(1 50</w>
( ></w>
z ing</w>
visc eral</w>
toler ated.</w>
ta st
stren g
strate gy</w>
sten osis</w>
sed ation,</w>
remo val</w>
polymer ase</w>
pentylenetetra z
patient s;</w>
on ly.</w>
nic ardi
ng/ ml</w>
na ive</w>
metr on
m ary</w>
great ly</w>
g er
evalu ating</w>
dro p</w>
deli vered</w>
degener ative</w>
contrac tility</w>
catalep sy,</w>
c rac
b red</w>
arb oxyl
apparen tly</w>
anti inflammatory</w>
adoles c
T or
S u
R el
Phen y
Na +
L- dopa</w>
Fancon i</w>
8 00</w>
0.0 1</w>
y lo
ver b
ven lafax
tra ined</w>
therap ies</w>
t ation</w>
synerg istic</w>
su fentanil</w>
si rolim
sca ven
pre fer
post partum</w>
pentam idine</w>
par ad
ou gh</w>
other s</w>
octre otide</w>
nor adrenergic</w>
neurolep tics</w>
mus cim
mitoxantr one</w>
manifest ation</w>
li um</w>
ist s</w>
impro ves</w>
hypo thermia</w>
hyper thermia</w>
headache .</w>
half- life</w>
ha ir</w>
go al</w>
gen it
epilep tiform</w>
enalap ri
em ul
diazepam ,</w>
di ffered</w>
brady kinin</w>
behavi or.</w>
allow ed</w>
W il
T oxicity</w>
T otal</w>
N ational</w>
N R
He mo
D SM-
Ch ild
AZ T</w>
9 7</w>
8 ),</w>
5-hydroxy trypt
(D O
( 60</w>
wom en,</w>
vitro .</w>
verb al</w>
tuberculo sis</w>
tri pt
st ages</w>
specimen s</w>
sim vastatin</w>
side- effect</w>
sensor ineural</w>
s ampl
r ag
progres sively</w>
proced ure.</w>
presum ably</w>
ph ases</w>
par tly</w>
p ure</w>
osmo tic</w>
oper ativel
monke ys.</w>
ml ,</w>
mannit ol</w>
labet alol</w>
ischem ia,</w>
intra operative</w>
inges tion.</w>
illust rates</w>
id .</w>
i si
hypo thalam
he i
gu ide
form ulation</w>
expres sion.</w>
examin ations</w>
ed ;</w>
deoxy chol
concer ning</w>
com pati
careful ly</w>
b arbit
analgesic s</w>
adriamyc in-induced</w>
acceler ated</w>
T B
Q -
Pro te
P e
Lith ium</w>
I U/
G P
B B
9 2</w>
3 90</w>
19 .
1. 1</w>
1 5%</w>
-1 00</w>
trans genic</w>
swit ched</w>
sub clinical</w>
st ed</w>
spec i
re combin
presc rib
potenti ate</w>
pl ant
par t,</w>
p.o .)</w>
or ing</w>
one- treated</w>
ograph y,</w>
obser ved,</w>
log istic</w>
le d.</w>
ket oro
iz es</w>
ish ing</w>
indic es</w>
id ation</w>
high- risk</w>
hemat uria</w>
group ).</w>
facilit ate</w>
f ind</w>
edi atric</w>
easi ly</w>
e a</w>
dy sp
dis comfor
del ta
colo rectal</w>
clin ic</w>
ce -
amil or
administ ering</w>
ad he
acro megal
ac coun
V as
Simil arly,</w>
O ut
H z</w>
GAB A-
C V
Bas el
AT RA</w>
A C</w>
5 8
3- 4</w>
(N MD
(MA P)</w>
( m
weigh t.</w>
week .</w>
ultras on
u tility</w>
typ ically</w>
transamin ase</w>
terat ogenic</w>
sub unit</w>
strok e.</w>
st ru
specific ity</w>
s l
r y
pro cess
placebo- controlled,</w>
pericardi al</w>
parox ysmal</w>
out .</w>
ouabain -induced</w>
on ia</w>
no dul
nitro s
necess it
mono amine</w>
mg/kg ;</w>
lign ocaine</w>
intra ventricular</w>
incid ences</w>
i.p. ).</w>
hippocamp us,</w>
experim ent,</w>
dialy sis.</w>
day ).</w>
contraceptiv es</w>
cap able</w>
c up
ax is.</w>
atheros clero
anti parkinsonian</w>
amitript yline</w>
aldehy de</w>
T T
S ec
Pati ent</w>
PGE 2</w>
Ig G</w>
ED 50</w>
D AT
A F</w>
3 %),</w>
18 0</w>
+/ -1.
( one</w>
( >
( 5-HT
zin c</w>
week s)</w>
war ran
test s,</w>
ston es</w>
stimul us</w>
sed ative</w>
s pro
r ated</w>
progno sis</w>
pre- existing</w>
per cutaneous</w>
pa re
ot opic</w>
modul ate</w>
microg/ kg</w>
metabol ism.</w>
mes enteric</w>
man .</w>
main taining</w>
locomo tion</w>
is ing</w>
inter view
inten si
id -induced</w>
hypertroph y.</w>
hemat ological</w>
he pt
function ing</w>
fati gu
ect opic</w>
ec tion.</w>
dyskine sia.</w>
don or</w>
develop ment.</w>
contr al
classi fied</w>
arrhyth mo
anti platelet</w>
anesthe tics</w>
aldo sterone</w>
ak athi
aggreg ation</w>
admis sion,</w>
abs ent</w>
S ch
Ret ro
RF -1
R ole</w>
PGE 1</w>
E uro
CY P</w>
Be fore</w>
B U
A spir
5 6
% );</w>
vent ro
ut ri
ultras ound</w>
succinyl chol
str ych
resul ts,</w>
res .</w>
refl ect</w>
opoi etic</w>
ocic ept
nit rous</w>
mut ation</w>
mo de</w>
micro M</w>
li ver,</w>
lev of
kg(-1 ),</w>
in direct</w>
ic ot
hydr amine</w>
hemorrh age,</w>
favor able</w>
fail ure
es tic
dep ri
con striction</w>
compati ble</w>
com e</w>
cl as
bra inst
ardi zed</w>
abnormal ities,</w>
S K
Rec ently,</w>
R R</w>
Pro t
OUT COM
OUTCOM E</w>
M us
H z
H ere</w>
Experim ental</w>
EP O</w>
tur no
there after
survi ved</w>
strategi es</w>
stit ute</w>
solub le</w>
si der
shi ft</w>
saf et
sac char
s one</w>
ro ute</w>
raz ole</w>
ran ulo
r un
put ative</w>
patient s),</w>
pall id
open- label</w>
month -old</w>
mode st</w>
microscop y.</w>
me tri
me flo
m ir
lisin opril</w>
initi ating</w>
ine- related</w>
immunosup pression</w>
ill ing</w>
h ind
h en
great est</w>
gen cy</w>
fun g
ep ide
endoc rine</w>
end- stage</w>
dyst onic</w>
diltiaz em
dig ox
d- release</w>
cor tic
condition ing</w>
complex es</w>
bra in,</w>
blind ed</w>
benzodiazep ines</w>
avail ability</w>
aten olol</w>
arabino side</w>
ar abine</w>
anc er</w>
adjust ment</w>
ab users</w>
[ CI
V entr
Symptom s</w>
St at
Pac litax
Nit ro
Jap anese</w>
F E
5 %),</w>
4 ;</w>
(OH) 2
( odds</w>
( U
wom en
toler ated,</w>
thyroidis m</w>
thal idom
termin ated</w>
su med</w>
stro ph
spir onolact
si s:</w>
sett ing.</w>
sept al</w>
seiz ure.</w>
ru pt</w>
ondan setron</w>
moder ately</w>
mo stly</w>
kg -1,</w>
intub ation</w>
in da
h ome
gly cemia</w>
expl ore</w>
es ).</w>
e ).</w>
dow n</w>
dis opyramide</w>
dis appearance</w>
demonst rating</w>
comp uter
comp ul
com a.</w>
centr ally</w>
ce l
calcineur in</w>
as eptic</w>
antin ociception</w>
anti viral</w>
anat om
al f
T D
ST- segment</w>
S D)</w>
P AC
Me as
M ice</w>
Le ft</w>
II I
HIV- infected</w>
H b</w>
Ev idence</w>
DX R</w>
CA 3</w>
B H
Ace t
3 %).</w>
0. 2
( i.v.)</w>
z il</w>
we ver</w>
vari ation</w>
vari abl
uter o</w>
tic -
significant ly.</w>
sertr aline</w>
proced ures.</w>
physos tigmine</w>
penicill in</w>
patient -
pa ired</w>
non- small</w>
micro angio
methylphen idate</w>
matri x</w>
mal on
ma x</w>
long- acting</w>
lidoca ine,</w>
lac tic</w>
l ac</w>
ful ness</w>
discontinu ation.</w>
diarrhe a</w>
dat a,</w>
consider ably</w>
clo sed</w>
challeng ed</w>
b ase</w>
artic le</w>
aro und</w>
ar ti
ar -
amplit u
acqu isi
Td P</w>
NSAID s</w>
LI D</w>
Hy po
De pression</w>
Assess ment</w>
AN CA</w>
14 ,</w>
1 %),</w>
0. 25</w>
( at</w>
% -
ven ti
understo od.</w>
unc er
treatment s.</w>
to wards</w>
ter .</w>
st radi
som at
sequel ae</w>
re :</w>
radio therapy</w>
prece ding</w>
praz ole</w>
pharmaco dynamic</w>
p tive</w>
ot rig
mmHg ,</w>
minut es,</w>
mam mary</w>
malform ations</w>
lo st</w>
kg ro
intoxic ation.</w>
inos it
implant ation</w>
ia )</w>
hypertroph ic</w>
hyper baric</w>
hemo dynamics</w>
haloth ane-
gon ad
g .</w>
f ar</w>
exclu ded.</w>
ester n</w>
es are
def ovir</w>
dec i
cyclophosphamide ,</w>
cul ture</w>
conf usion</w>
az ot
awa reness</w>
atax ia</w>
aspir in,</w>
ac ted</w>
a ur
M or
M any</w>
Gi ven</w>
GF R</w>
Cor onary</w>
C ent
A z
2. 4</w>
vecur onium</w>
ve di
transplant ed</w>
suppres s</w>
suppor ted</w>
s patial</w>
regimen s.</w>
recept or.</w>
reac tions,</w>
promot ing</w>
proca ine</w>
pr one</w>
p sor
oxid ation</w>
oc hemic
observ ational</w>
o tic</w>
nitro gen</w>
micro M)</w>
mic tur
mg/ day.</w>
man ip
line zol
kind ling</w>
isch aemic</w>
intr act
inter nal</w>
inter mediate</w>
ing s.</w>
imi pr
idi osyn
h loro
form alin</w>
fol low</w>
fib rate</w>
ethambut ol</w>
endo theli
en si
en anti
ecti n</w>
contro ver
contrac tions</w>
co administration</w>
cholester ol
behavi our
asp ects</w>
am ate</w>
addi tive</w>
a /
W estern</w>
Th al
T rans
Hep at
H IT
C 3
Basel ine</w>
9 1</w>
7 1</w>
5 %).</w>
4. 5</w>
2 6.
(C O
vi ro
tremor ,</w>
tion ed</w>
tion :</w>
time -
ticlop idine</w>
ter ,</w>
system atic</w>
syn thesi
si c</w>
s he
repolar ization</w>
remo ved</w>
re adily</w>
ph il
pel v
out patients</w>
otec an</w>
oc occ
normal ization</w>
neon ates</w>
meth oxy
meth amphetamine-induced</w>
man aged</w>
leng th
ibu profen
hyper ammon
hist ology</w>
hepat ocytes</w>
hemat oc
fol ate</w>
fi g
f loxacin</w>
event ually</w>
esare an</w>
erythropoi etin</w>
e /
dram atic</w>
dop amine-
de pos
contral ateral</w>
complic ations,</w>
com promis
colon y-
children ,</w>
cardio protective</w>
calcitri ol</w>
av es</w>
aqu eous</w>
aminonucle o
all ed</w>
adrenal ine-induced</w>
acyclo vir</w>
activ ation.</w>
Val pro
Uni versity</w>
Repe ated</w>
O ver</w>
N K
M agne
M ).</w>
HU S</w>
Bra in</w>
Al ter
A no
A (2
2. 3</w>
(-/- )</w>
z ine</w>
vincrist ine-induced</w>
traum atic</w>
tr ue</w>
tox in</w>
te m</w>
sib ility</w>
se c</w>
s ine</w>
ro pivacaine</w>
repeti tive</w>
recor ding</w>
qu ad
py r
psych omotor</w>
propylthio uracil</w>
prompt ly</w>
pro pafen
pilocarp ine,</w>
phen ic
on uc
omime tic</w>
olig uric</w>
n ocicept
my co
mus cles</w>
meta -
ment ation</w>
m -
lymph ocytic</w>
lo mer
lipo protein</w>
lethal ity</w>
le g</w>
j ac
intract able</w>
insti ll
in contin
fl ush
eryth ema</w>
efficac ious</w>
di phenyl
cys tic</w>
cyclospor in</w>
cou pl
concentr ation,</w>
compul sive</w>
cocaine- related</w>
coag ul
cisplat in,</w>
cis -
circul atory</w>
challeng e.</w>
cap ecit
c Tn
bupivaca ine.</w>
basel ine.</w>
az ol</w>
as alazine</w>
am phenic
am ous</w>
aden os
accumb ens</w>
R ),</w>
N ,</w>
Hodg kin
D ay</w>
Ar g
8 3</w>
1 1-
(N O)</w>
(N O
( the</w>
warran ted.</w>
ur ally</w>
thre e-
ter ious</w>
sulpiri de</w>
st as
seg mental</w>
ro ot</w>
rin one</w>
resc ue</w>
pro -
per cep
olog ous</w>
no v
mor ning</w>
micrograms/ kg/
m urine</w>
lat er
lamivud ine-
k ine</w>
insuffici ency.</w>
inhibit ors,</w>
in uria</w>
ic lo
hyperalgesi a,</w>
hydr ation</w>
gen der</w>
form ed</w>
fibr in
exer ted</w>
et op
enanti om
discharg es</w>
day s).</w>
day -old</w>
combin ation.</w>
com orb
can di
c li
block er,</w>
bicucul line</w>
antine oplastic</w>
anore x
am lodipine</w>
advant age</w>
ac k</w>
a vi
U l
Physi ci
LVE F</w>
K +
Iso proteren
Inc idence</w>
INTERVEN TIONS:</w>
Hg )</w>
H a
GS H</w>
E P</w>
D ).</w>
COX- 2</w>
A dul
ve lop
ul a</w>
tw or
ti r
t un
sup ine</w>
sulf on
slow ly</w>
shi f
s in</w>
repor t,</w>
renin- angiotensin</w>
regul atory</w>
pri de</w>
pre cur
pp m</w>
ph ent
pa ir</w>
or d
onuc lide</w>
on d</w>
ome g
nitroprus side-induced</w>
morph ology</w>
mitochond ria</w>
m M</w>
lig ation</w>
leuk openia</w>
less er</w>
know n,</w>
it s,</w>
it ,</w>
intra ocular</w>
ingest ed</w>
indic ative</w>
increas ed,</w>
ic .</w>
he im
h ab
follow-up ,</w>
fluoresc ence</w>
e ar</w>
dr y</w>
dipyridamol e-induced</w>
degrad ation</w>
de d,</w>
d ang
cult ures</w>
cra ving</w>
complain ts</w>
clonid ine.</w>
bran ch</w>
bo dy
bac kgro
b ru
ay s.</w>
as cit
ap aro
alcoh olic</w>
adoles cent</w>
Ventr icular</w>
T ak
S S</w>
S BP</w>
MD MA</w>
M T</w>
M PT
J un
In te
Grou p.</w>
G V
Fo od</w>
F atal</w>
F ).</w>
E 1</w>
7 ),</w>
5 /
2 3.
- based</w>
vac c
tiz ing</w>
t es</w>
sub -
s pl
s clerosis</w>
recipi ents.</w>
re jection</w>
prescrib ing</w>
pre operative</w>
pos t</w>
per ative</w>
pat ch
p tion.</w>
ove rex
om yo
om as.</w>
mg/d L</w>
ket ocon
iohex ol</w>
ing )</w>
inflamm ation.</w>
impair ments</w>
immunore active</w>
id ine-induced</w>
hospital ization</w>
hormon es</w>
gab ap
g an
fer ri
ex pan
epilept ogenic</w>
enh ancing</w>
dos age.</w>
dog .</w>
depress ant</w>
def ine</w>
conjunc tion</w>
classi cal</w>
cap sul
bri le</w>
b asic</w>
adrenocept ors</w>
adolesc ents</w>
abol ic</w>
W K
Rec o
R s</w>
N D
L ocal</w>
L P
In f
IC U</w>
IC RF-1
Hodgkin 's</w>
H emat
CA )</w>
C ancer</w>
AIM :</w>
6 ;</w>
6 0-
4 %,</w>
20 00</w>
2 4.
0 -1
( 8</w>
we an
vit al</w>
traum a</w>
tra di
tissu e.</w>
thrombocytopen ia.</w>
surviv ors</w>
str al</w>
stimul ation,</w>
stand ardized</w>
st ent</w>
st atic</w>
so ft</w>
side .</w>
sec tional</w>
ri gh
reli able</w>
rele ased</w>
recombin ant</w>
rat e-
rat ,</w>
provo ked</w>
prost atic</w>
prolact in
pect or
ob ses
neo plas
ne os
nar co
mut ations</w>
mor tem</w>
month s)</w>
m isoprost
lymph ocyte</w>
log raph
invol ves</w>
impro ving</w>
i -
hyper activity.</w>
high ligh
ga ve</w>
fl are</w>
exacerb ated</w>
es ),</w>
er )</w>
efficac y,</w>
e ligible</w>
di methyl
develop ed.</w>
decreas ed.</w>
de myel
cri tically</w>
cont ex
con sol
coll ap
clar ify</w>
captop ri
ca v
asth ma</w>
ass ay.</w>
analgesi a.</w>
ST Z
MT X
M orph
Inhib ition</w>
G ra
Ch ol
Al z
A ).</w>
1/ 2</w>
1 %).</w>
-1 7</w>
(i )</w>
treatment -
transf usion</w>
table ts</w>
system s.</w>
